A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a tertiary hospital, South Africa

By Yasmina Johnson

JHNYAS001

SUBMITTED TO THE UNIVERSITY OF CAPE TOWN

In partial fulfilment of the requirements for the degree

MASTER OF PUBLIC HEALTH: HEALTH ECONOMICS

In the School of Public Health and Family Medicine, Health Sciences Faculty

University of Cape Town

March 2016

Supervisor:

Edina Sinanovic
Associate Professor
Director: Health Economics Unit
Head: Health Economics Division
School of Public Health & Family Medicine, Health Sciences Faculty
University of Cape Town

Co-supervisor:

Professor Jennifer Moodley
Cancer Research: Faculty of Health Sciences; and School of Public Health & Family Medicine
University of Cape Town

Co-supervisor:

Professor Paul Goldberg
Head: E22 Colorectal Unit
Groote Schuur Hospital
University of Cape Town
The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non-commercial research purposes only.

Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author.
DECLARATION

I, Yasmina Johnson, hereby declare that the work on which this dissertation / thesis is based is my original work (except where acknowledgements indicate otherwise) and that neither the whole work nor any part of it has been, is being, or is to be submitted for another degree in this or any other university.

I empower the university to reproduce for the purpose of research either the whole or any portion of the contents in any manner whatsoever.

Signature: [Signature]

Date: 10 March 2017
Dedication

To Fazel, I could not have done this without you.

To my family, all of you, THANK YOU.
Abstract

Individuals with Lynch Syndrome (LS) have a 25% to 75% lifetime risk of colorectal cancer and the cancer generally presents at an early age. Establishing the costs of strategies to prevent or delay the onset of cancer is, thus, desirable. This study compared the cost of two screening approaches - colonoscopy only (Strategy 1) versus genetic testing for LS followed by colonoscopy for the individuals that tested positive for LS (Strategy 2).

A comparative cost analysis was conducted at a tertiary hospital, from the health provider perspective, using a micro-costing, ingredient approach. Probands that were selected, according to the Revised Bethesda Criteria, for genetic testing between 01 November 2014 and 30 October 2015, and their first degree relatives (high risk relatives) were evaluated according to Strategy 1 and Strategy 2. Total costs per strategy were estimated and compared. Sensitivity analyses were performed on adherence rates to colonoscopy, positivity rates of relatives and discount rates.

A total of 40 families were studied. The total cost for Strategy 1 amounted to R4 932 718 ($332 617) compared to R390 308 ($26 319) for Strategy 2 (Discount rate 3%; Adherence 75% and Positivity rate of relatives 45%). Base case analysis indicated a difference of 92% less in the total cost for Strategy 2 compared to Strategy 1. Univariate sensitivity analyses showed that the difference in cost between the two strategies was not sensitive to changes in discount rates, adherence rates or positivity rates of relatives.

Compared to colonoscopy screening only, colonoscopy combined with genetic testing presented a less costly option by identifying patients at high risk of colorectal cancer for screening. Testing of relatives should be facilitated since, compared to probands, genetic testing of relatives is less costly and is likely to have more benefit. Effectiveness of the screening programmes should be established through further research.
Acknowledgements

Thank you to Alina Esterhuizen (NHLS), Andy Cunningham (DOH: Public Works), Lorraine Rademeyer (DOH: Public Works), Nazneen Rawoot (Pharmacy: GSH), Sr S Diedericks (E23: GSH) and GSH management for your support.

Ebrahim Samsodien, thank you, for your invaluable support in assisting me with the financial information.

Sr Mare Van Wyk, thank you for your patience, your guidance on colonoscopy, and making time in your busy days to assist me. Without your input I would have been lost.

Sr Ursula Algar – thank you for your encouragement and making me not feel like a fool, for providing me with the information I required and looking up records for me, and explaining concepts…and ….and….and… thank you very much.

Alvera Vorster – I must have been a daunting challenge, with my limited knowledge on genetics. Thank you for sticking with me and for making this dissertation possible for me.

Prof Raj Ramesar – you always made me feel welcome, thank you for your guidance and input, it is very much appreciated.

Dr Kathryn Chu – you never met me, and still you took the time and effort to provide me with excellent advice – thank you so much.

To my co-supervisors, Prof Jennifer Moodley and Prof Paul Goldberg – you presented the request – and that was the start of everything. Thank you for your input in this work.

Professor Edina Sinanovic – I could not have asked for a better supervisor. I was amazed every time we met how you managed to zoom into the real issues and smoothly got me on the right path. I am so appreciative of the patience and guidance you showed me. I do not have words to thank you – you are amazing!!
<table>
<thead>
<tr>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of contents</td>
<td>1A</td>
</tr>
<tr>
<td>List of tables</td>
<td>5A</td>
</tr>
<tr>
<td>List of figures</td>
<td>6A</td>
</tr>
<tr>
<td>Abbreviations, acronyms</td>
<td>7A</td>
</tr>
<tr>
<td>Glossary</td>
<td>8A</td>
</tr>
</tbody>
</table>

**TABLE OF CONTENTS**

**PART A: PROTOCOL**

1 Background and rationale
   1.1 Background                                    2
   1.2 Problem statement                             3
   1.3 Rationale and justification of study          4
   1.4 Literature review                             6
      1.4.1 Lynch Syndrome                            6
      1.4.2 Diagnosis and screening of Lynch Syndrome 7
      1.4.3 Cost-effectiveness studies on screening strategies for Lynch Syndrome 9

2 Aims, objectives and conceptual framework
   2.1 Aim                                          11
   2.2 Objectives                                   12
   2.3 Conceptual framework                         13

3 Method
   3.1 Study design                                 13
   3.2 Setting and population                       13
   3.3 Screening strategies                         15
   3.4 Cost analysis                                17
   3.5 Sensitivity analysis                         21
   3.6 Assumptions                                  22
PART A: PROTOCOL - continued

4 Data analysis and management 22
5 Ethical considerations 23
  5.1 Potential benefits and risks 23
  5.2 Autonomy and informed consent 23
  5.3 Confidentiality 23
  5.4 Ethical approval 23
6 Publication and dissemination 24
7 Logistics 24
8 Budget 24
  References 25

PART B: STRUCTURED LITERATURE REVIEW

1 Introduction 2
2 Update on Lynch Syndrome 4
3 Aetiology 5
4 Prevalence and risk 6
5 Diagnosing Lynch Syndrome 9
  5.1 Family history and computational models 10
  5.2 Immunohistochemistry 11
  5.3 Microsatellite Instability 11
  5.4 BRAF V600E 12
  5.5 Genetic testing 13
    5.5.1 Universal testing 14
    5.5.2 Traditional testing 15
    5.5.3 Genetic testing procedures 18
<table>
<thead>
<tr>
<th>PART B: STRUCTURED LITERATURE REVIEW - continued</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Genetic counselling and patient support</td>
<td>19</td>
</tr>
<tr>
<td>7 Screening for colorectal cancer</td>
<td>19</td>
</tr>
<tr>
<td>8 Cost analysis</td>
<td>22</td>
</tr>
<tr>
<td>9 Cost-effectiveness of screening strategies for Lynch Syndrome</td>
<td>29</td>
</tr>
<tr>
<td>10 Summary of literature review</td>
<td>31</td>
</tr>
<tr>
<td>11 Conclusion</td>
<td>33</td>
</tr>
<tr>
<td>References</td>
<td>34</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PART C: JOURNAL ARTICLE</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract</td>
<td>2</td>
</tr>
<tr>
<td>1 Introduction</td>
<td>3</td>
</tr>
<tr>
<td>2 Method</td>
<td>6</td>
</tr>
<tr>
<td>2.1 Study design and objectives</td>
<td>6</td>
</tr>
<tr>
<td>2.2 Screening strategies</td>
<td>6</td>
</tr>
<tr>
<td>2.3 Setting and population</td>
<td>7</td>
</tr>
<tr>
<td>2.4 Colonoscopy</td>
<td>8</td>
</tr>
<tr>
<td>2.5 Genetic testing procedures</td>
<td>9</td>
</tr>
<tr>
<td>2.6 Cost analysis</td>
<td>10</td>
</tr>
<tr>
<td>2.7 Sensitivity analysis</td>
<td>13</td>
</tr>
<tr>
<td>3 Results</td>
<td>14</td>
</tr>
<tr>
<td>3.1 Cost analysis</td>
<td>14</td>
</tr>
<tr>
<td>3.2 Base case analysis</td>
<td>18</td>
</tr>
<tr>
<td>3.3 Sensitivity analysis</td>
<td>18</td>
</tr>
<tr>
<td>4 Discussion</td>
<td>19</td>
</tr>
<tr>
<td>5 Conclusion</td>
<td>23</td>
</tr>
<tr>
<td>6 Limitations</td>
<td>23</td>
</tr>
<tr>
<td>References</td>
<td>23</td>
</tr>
</tbody>
</table>
PART D: APPENDICES

1 Supplementary material
   1.1 Examples of cost allocations and calculations tables 2
   1.2 Analysis of probands and relatives 3-5
   1.3 Base Case analysis table 6

2 Consent form 7

3 Letter of approval from Human Research Ethics Committee 12

4 Permission to proceed with research – Groote Schuur hospital 13

5 Change of dissertation title 14

6 Instructions for author for journal article 15

PART E: POLICY BRIEF

Key messages 2

Introduction 2

Objectives 5

Method 5

Key findings 5

Policy recommendations 6
<table>
<thead>
<tr>
<th>LIST OF TABLES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PART A: PROTOCOL</strong></td>
<td></td>
</tr>
<tr>
<td>Table 1</td>
<td>11</td>
</tr>
<tr>
<td>Base case estimates of costs of routine testing and colonoscopy for Lynch Syndrome in patients with colorectal cancer and first degree relatives, in 2014 US $</td>
<td></td>
</tr>
<tr>
<td>Table 2</td>
<td>13</td>
</tr>
<tr>
<td>Conceptual framework for estimating costs per screening strategy</td>
<td></td>
</tr>
<tr>
<td>Table 3</td>
<td>18</td>
</tr>
<tr>
<td>Identification, measurement and valuation of type of costs</td>
<td></td>
</tr>
<tr>
<td>Table 4</td>
<td>24</td>
</tr>
<tr>
<td>Study time lines</td>
<td></td>
</tr>
<tr>
<td><strong>PART B: STRUCTURED LITERATURE REVIEW</strong></td>
<td></td>
</tr>
<tr>
<td>Table 1</td>
<td>10</td>
</tr>
<tr>
<td>Revised Bethesda Criteria</td>
<td></td>
</tr>
<tr>
<td>Table 2</td>
<td>24</td>
</tr>
<tr>
<td>Base case estimates of costs of routine testing and colonoscopy for Lynch Syndrome in patients with colorectal cancer and first degree relatives, in 2014 US $</td>
<td></td>
</tr>
<tr>
<td><strong>PART C: JOURNAL ARTICLE</strong></td>
<td></td>
</tr>
<tr>
<td>Table 1</td>
<td>15</td>
</tr>
<tr>
<td>Annual and unit cost by category for colonoscopy, presented in 2016 Rand and US $</td>
<td></td>
</tr>
<tr>
<td>Table 2</td>
<td>15</td>
</tr>
<tr>
<td>Costs of genetic counselling for diagnosing Lynch Syndrome for probands and their 1&lt;sup&gt;st&lt;/sup&gt; degree relatives, presented in 2016 Rand and US $</td>
<td></td>
</tr>
<tr>
<td>Table 3</td>
<td>16</td>
</tr>
<tr>
<td>Cost of genetic testing for diagnosing Lynch Syndrome in probands and their 1&lt;sup&gt;st&lt;/sup&gt; degree relatives, presented in 2016 Rand and US $</td>
<td></td>
</tr>
<tr>
<td>Table 4</td>
<td>17</td>
</tr>
<tr>
<td>Cost by category of genetic testing procedure for diagnosing Lynch Syndrome in probands tested between 01 November 2014 and 30 October 2015, and their 1&lt;sup&gt;st&lt;/sup&gt; degree relatives, presented in 2016 Rand and US $</td>
<td></td>
</tr>
<tr>
<td>Table 5</td>
<td>17</td>
</tr>
<tr>
<td>Total cost per screening strategy based on utilisation, presented 2016 Rand and US $</td>
<td></td>
</tr>
<tr>
<td><strong>PART D: APPENDICES</strong></td>
<td></td>
</tr>
<tr>
<td>S1 Table</td>
<td>2</td>
</tr>
<tr>
<td>Example: Personnel costs estimation per unit (minute) for colonoscopy (or genetic testing)</td>
<td></td>
</tr>
<tr>
<td>S2 Table</td>
<td>2</td>
</tr>
<tr>
<td>Example: Estimation of building cost for colonoscopy (or genetic test)</td>
<td></td>
</tr>
<tr>
<td>S3 Table</td>
<td>2</td>
</tr>
<tr>
<td>Example: Estimation of equipment cost for colonoscopy (or genetic test)</td>
<td></td>
</tr>
<tr>
<td>S4 Table</td>
<td>2</td>
</tr>
<tr>
<td>Example: Estimation of consumables and reagents for genetic testing</td>
<td></td>
</tr>
<tr>
<td>S5 Table</td>
<td>6</td>
</tr>
<tr>
<td>Percentage difference in total costs of colonoscopy screening between the base case and Strategy 1 and 2 at various discount rates, adherence rates and positivity rates of relatives, presented in 2016 Rand and US $</td>
<td></td>
</tr>
</tbody>
</table>
### LIST OF FIGURES

#### PART B: STRUCTURED LITERATURE REVIEW

<table>
<thead>
<tr>
<th>Fig</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Universal screening</td>
<td>14</td>
</tr>
<tr>
<td>2</td>
<td>Traditional testing strategy in the case of a known family mutation</td>
<td>15</td>
</tr>
<tr>
<td>3</td>
<td>Traditional testing strategy in the case where the patient is clinically affected and has an unknown family mutation</td>
<td>16</td>
</tr>
<tr>
<td>4</td>
<td>Traditional testing strategy in the case of an at-risk patient (do not have cancer yet) and an unknown family mutation</td>
<td>17</td>
</tr>
</tbody>
</table>

#### PART C: JOURNAL ARTICLE

<table>
<thead>
<tr>
<th>Fig</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Impact of discount rates, adherence rates and positivity rates of relatives on the cost difference between Strategy 1 and Strategy 2</td>
<td>19</td>
</tr>
</tbody>
</table>

#### PART D: APPENDICES

<table>
<thead>
<tr>
<th>S1 Fig</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Demographic analysis per screening Strategy 1 of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives</td>
<td>3</td>
</tr>
<tr>
<td>S2 Fig</td>
<td>Demographic analysis per screening Strategy 2 of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives</td>
<td>4</td>
</tr>
<tr>
<td>S3 Fig</td>
<td>Analysis per screening strategy of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives</td>
<td>5</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>BAS</td>
<td>Basic Accounting System</td>
<td></td>
</tr>
<tr>
<td>CBA</td>
<td>Cost benefit analysis</td>
<td></td>
</tr>
<tr>
<td>CEA</td>
<td>Cost effective analysis</td>
<td></td>
</tr>
<tr>
<td>CRC</td>
<td>Colorectal cancer</td>
<td></td>
</tr>
<tr>
<td>CSIR</td>
<td>Council for Scientific and Industrial Research</td>
<td></td>
</tr>
<tr>
<td>CUA</td>
<td>Cost utilisation analysis</td>
<td></td>
</tr>
<tr>
<td>DBSA</td>
<td>The Development Bank of South Africa</td>
<td></td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
<td></td>
</tr>
<tr>
<td>DOH</td>
<td>Department of Health</td>
<td></td>
</tr>
<tr>
<td>DPSA - COLA</td>
<td>Department of Public Service and Administration – Cost of Living Adjustments</td>
<td></td>
</tr>
<tr>
<td>EPCAM</td>
<td>Epithelial cell adhesion molecule</td>
<td></td>
</tr>
<tr>
<td>EGAPP</td>
<td>Evaluation of Genomic Applications in Practice and Prevention</td>
<td></td>
</tr>
<tr>
<td>FDR</td>
<td>First degree relative</td>
<td></td>
</tr>
<tr>
<td>FOBT</td>
<td>Faecal occult blood test</td>
<td></td>
</tr>
<tr>
<td>GSH</td>
<td>Groote Schuur hospital</td>
<td></td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
<td></td>
</tr>
<tr>
<td>HREC</td>
<td>Human Research Ethics Committee</td>
<td></td>
</tr>
<tr>
<td>ICER</td>
<td>Incremental cost-effectiveness ratio</td>
<td></td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
<td></td>
</tr>
<tr>
<td>LS</td>
<td>Lynch Syndrome</td>
<td></td>
</tr>
<tr>
<td>MLH1</td>
<td>MutL homologue 1</td>
<td></td>
</tr>
<tr>
<td>MLPA</td>
<td>Multiplex ligation-dependent probe amplification</td>
<td></td>
</tr>
<tr>
<td>MSH2</td>
<td>MutS homologue 2</td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>Mismatch repair</td>
<td></td>
</tr>
<tr>
<td>MSH6</td>
<td>MutS homologue 6</td>
<td></td>
</tr>
<tr>
<td>MSI</td>
<td>Microsatellite instability</td>
<td></td>
</tr>
<tr>
<td>NDOH</td>
<td>National Department of Health</td>
<td></td>
</tr>
<tr>
<td>NHLS</td>
<td>National Health Laboratory Services</td>
<td></td>
</tr>
<tr>
<td>NGS</td>
<td>Next-generation sequencing</td>
<td></td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase chain reaction</td>
<td></td>
</tr>
<tr>
<td>PMS2</td>
<td>Postmeiotic segregation increased 2</td>
<td></td>
</tr>
<tr>
<td>QUALY</td>
<td>Quality adjusted life years</td>
<td></td>
</tr>
<tr>
<td>UCT</td>
<td>University of Cape Town</td>
<td></td>
</tr>
</tbody>
</table>
### Glossary

**BRAF V600E**

A *BRAF* gene mutation identified in a number of cancers, including colorectal cancer.

---

**Incremental cost-effectiveness ratio**

In a specific population, the difference in the average cost of two interventions divided by the difference in the average outcomes of the two interventions.

---

**Predictive testing**

Testing for a mutation that is known.

---

**Proband**

The first medically identified individual in a family affected with a disorder and serves as the starting position for the genetic study of the family.

---

**Sporadic colorectal cancer**

Colorectal cancer that does not appear to have an hereditary feature.

---

**Polymerase chain reaction (PCR)**

A method used to amplify DNA sequences.

---

**First degree relative**

A relative that is a parent, sibling or child.
PART A: PROTOCOL

A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a tertiary hospital, South Africa
1. **Background and rationale**

1.1 **Background**

Lynch Syndrome is clinically defined as a disorder that predisposes individuals to colorectal cancer, endometrial cancer and certain other cancers as a result of an underlying germline mismatch repair (MMR) gene mutation (Vasen et al. 2013). The disorder presents with high rates of multiple primary tumours, has an early age of onset and generally has an absence of typical risk factors (Vasen et al. 2013). Carriers of a mutation in any of the mismatch-repair (MMR) genes have a lifetime risk for colorectal cancer of 25% to 75%, compared to a lifetime risk 5% in the general population (Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al. 2013). Lynch Syndrome includes individuals with existing cancers as well as those who have not yet developed cancer (Palomaki et al. 2009).

Worldwide, colorectal cancer is noted as the third most common cancer and cause of cancer-related deaths (Graham et al. 2012). In 2008, colorectal cancer accounted for more than 600 000 deaths of which 70% occurred in low and middle income countries (Graham et al. 2012). In South Africa, colorectal cancer is the fifth most common cancer, with approximately 4 697 new cases and 3 138 deaths reported in 2012 (National Health Laboratory Services: Globocan, 2015). Just over 50% of the new cases diagnosed and 41% of deaths were in persons less than 65 years old (Globocan 2015). The most common cause of hereditary colorectal cancer is Lynch Syndrome which accounts for approximately 3% to 5% of all colorectal cancers (Bonadona et al. 2011; Snowsill et al. 2014). Other than the Lynch Syndrome register maintained by the University of Cape Town (UCT), there are few hereditary colorectal cancer registers in South Africa (Coetzee et al. 2013). To date, this register has recorded 61 families who mainly live in the Western Cape and Northern Cape areas (Voster, A: Division of Human Genetics: UCT, personal communication 2015).
1.2 Problem Statement

Individuals with Lynch Syndrome have an elevated risk for developing cancer, with the highest risk for colorectal cancer (Snowsill et al. 2014). Estimated lifetime risks for colorectal cancer of 25% to 75% have been reported in many studies (Snowsill et al. 2014). Progression of adenoma to carcinoma is approximately five times more accelerated in individuals with Lynch Syndrome compared to sporadic and familial colorectal cancers (Snowsill et al. 2014; Vasen et al. 2013). Furthermore, colorectal cancer is generally asymptomatic until it has reached an advanced stage. For these reasons an effective screening programme is fundamental for early detection and successful management of colorectal cancer (Snowsill et al. 2014 & Vasen et al. 2013).

Colonoscopy is the only screening programme that has proved to be effective for these individuals (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014). Two main advantages of appropriate screening are the early detection of cancer and consequently improved chances of curative treatment and secondly, the early detection of pre-cancerous lesions which allows for removal of the polyps before it progresses to cancer. Studies have shown that effective colonoscopy screening programmes reduced mortality by 65% to 72% (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014). Stupart et al. (2009) showed an 80% decrease in mortality in a South African study.

Though sufficient evidence exists of the valuable benefits, formal colonoscopy screening programmes do not exist for individuals with Lynch Syndrome in South Africa (Thomson, S: Gastroenterology clinic: Groote Schuur hospitals, personal communication 2015). Public sector colonoscopy services, that service approximately 80% of the country’s population, are few and predominantly limited to secondary and tertiary level care. Colonoscopies are performed by medical or surgical gastroenterologists only, which contributes to the high cost
of the service. Due to the limited professional skills and services available, colonoscopies are generally not provided for screening purposes, but are performed on patients that already present with symptoms in order to exclude cancer (Thomson, S: Gastroenterology clinic: Groote Schuur hospitals, personal communication 2015).

In a resource constrained environment, accurate prediction of individuals at high risk of colorectal cancer who will benefit from colonoscopy screening and leaving those at low risk of disease unexposed to potentially invasive screening procedures, will reduce the burden on services as well as optimise the use of scarce resources (Snowsill et al. 2014). Genetic testing is the only method to confirm a diagnosis for Lynch Syndrome and evidence suggested that it is a cost-effective and reliable strategy to identify individuals for colonoscopy screening (Snowsill, et al. 2014). Furthermore, genetic testing combined with immunological testing is the preferred strategy in terms of cost-effectiveness (Palomaki et al 2009; Mvundura et al. 2010; Ladabaum et al. 2011; Snowsill, et al. 2014). The genetic testing service available for testing for Lynch Syndrome in patients from this study was provided on a research basis by the Human Genetics Research Unit in the Division of Human Genetics at the University of Cape Town (Ramesar, R: Division of Human Genetics: UCT, personal communication 2015).

The lack of genetic testing and colonoscopy screening programmes pose a major drawback for the management of colorectal cancer in individuals with Lynch Syndrome. Determining the costs of providing these services is one of the key initial steps to assessing affordability and successful implementation of such services.

1.3 Rationale and justification of study

Apart from the high risk rate associated with colorectal cancer in LS, these cancers occur, generally, before the age of 50 years with numbers beginning to increase noticeably from the
age of 30 years (Bonadona et al. 2011; Cohen et al. 2014; Snowsill et al 2014). This age range includes persons that are financially independent, economically active and support families. Preventing or delaying cancer onset, by appropriate screening strategies, would have health related, social and economic benefits for the country. It is, therefore, important to establish the cost of colonoscopy screening options as this would contribute to assessing affordability of such services to the health service provider.

Colonoscopy screening and clinical genetics have a strong emphasis on early detection and prevention of cancers which is in line with the National Department of Health’s strategic objective of enhanced wellness through primary, secondary and tertiary prevention (Department of Health: Western Cape. 2014). Also, the Western Cape Department of Health issued a genetic services policy framework for the province (Department of Health: Circular H212/2014). Services listed within the packages of care included genetic risk based on family history for e.g. cancers. The policy further specified the development of a “Rare Disease Policy” which should address the equitable rationing of scarce resources (Department of Health: Circular H212/2014). Results from this study would contribute to this policy by informing on the resource allocations and affordability of an effective Lynch Syndrome genetic testing programme.

No published study has assessed the cost implications associated with providing a formal public sector colonoscopy and genetic testing screening service for patients with Lynch Syndrome in South Africa. Evidence with regards to screening strategies for Lynch Syndrome suggested that targeted screening is cost-effective as opposed to no screening (Snowsill et al. 2014). Almost all of these studies were conducted in high income countries and generalisability to the South African context is impractical as cost-effectiveness is largely context specific and linked to available resources and practices. (Buchanan et al 2013; Gray et al. 2012; Drummond et al. 2005; Snowsill et al 2014).
This study, therefore, aims to collect and analyse primary data specific to the South African context in order to compare the cost implications of two screening options from a provider’s perspective; i.e. colonoscopy screening for all Lynch Syndrome-suspected individuals versus targeted colonoscopy screening for the individuals diagnosed with Lynch Syndrome after genetic testing. Based on literature (Snowsill et al. 2014), it is hypothesised that targeted colonoscopy screening will reduce the number of patients requiring colonoscopy and will, thus present a less costly option.

1.4 Literature review

1.4.1 Lynch Syndrome

Lynch Syndrome (LS) is an autosomal dominant disorder that predisposes individuals to cancers, especially colorectal cancer (Cohen et al. 2014). A defect in the MMR system leads to loss of function of the entire MMR complex and an inability to restore base-base mismatches and small insertions and deletions in DNA sequences. This results in an accelerated accumulation of genetic mutations which often progresses to cancer. Mutations were found in one of the four MMR genes, \textit{MLH1, MSH2, MSH6} or \textit{PMS2}. More recently, deletions of the 3’ end of \textit{EPCAM} were reported and these deletions resulted in epigenetic hypermethylation of the \textit{MSH2} promoter, thereby resulting in LS (Cohen et al. 2014).

The risks of developing cancers associated with LS are continuing to evolve with the increased application of germline testing and these risks are highly MMR gene mutation and sex dependent (Snowsill et al. 2014; Cohen et al. 2014). For men the risk of colorectal cancer was reported to be higher than for women (38% - 45% vs 31% - 35%) (Bonadona et al. 2011; Giardiello et al. 2014). The highest risks, in the region of 40% to 70%, are associated with individuals with \textit{MLH1} and \textit{MSH2} mutations, with lower risks reported for \textit{MSH6} (10% - 22%) and \textit{PMS2} (15% - 22%) (Bonadona et al. 2011; Steinke et al. 2013;
MHL1 and MSH2 mutations were identified in the cohort recorded on the UCT DNA database, but to date no MSH6, PMS2 and EPCAM mutations were identified (Voster, A: Division of Human Genetics: UCT, personal communication 2015). The MMR mutation distribution in the UCT cohort indicates a population that falls in the highest risk category, reinforcing the need for an effective screening programme.

Unlike sporadic cancers that generally occur approximately after the age of 60 years, LS-associated colorectal cancers have an earlier onset, i.e. < 50 years old, and may occur as early as 25 years of age (Giardiello et al. 2014; Cohen et al. 2014; Vasen et al. 2013). The estimated cumulative risk in carriers was shown to increase from the age of 30 years irrespective of the gene mutation (Bonadona et al. 2011). Around 15% - 20% of cancer survivors with LS will develop a second colorectal cancer within 10 years, 40% - 50% within 20 years and >60% within 30 years (Cohen, et al. 2014). In LS, polyps may progress to carcinoma within 2 to 3 years as opposed to 8 to >10 years in the general population. For these reasons, evidenced-based guidelines recommend colonoscopy every 1 to 2 years as opposed to every ten years as per the general population (Cohen, et al. 2014; Snowsill et al. 2014; Giardiello et al. 2014; Vasen et al. 2013).

1.4.2 Diagnosis and screening of Lynch Syndrome

Diagnosis of Lynch Syndrome has progressed over the past two decades to include family history, histopathological characteristics and germline testing (Cohen et al. 2014).

Though family history is an important element in assessing risk in the general population, neither the Amsterdam criteria nor the Bethesda criteria delivers the necessary sensitivity and specificity as a preliminary screening test (Vasen et al. 2013; Giardiello et al. 2014). Faecal occult blood tests (FOBTs) detect mainly asymptomatic cancers by detecting blood
from bleeding cancers (Coetzee 2013). Sensitivity of a single FOBT is about 30% as cancers bleed intermittently. Although cheap and non-invasive, the low sensitivity of FOBT is not ideal for screening for LS. Flexible sigmoidoscopy is less demanding technically and less invasive than colonoscopy and does not require full bowel preparation. This procedure allows for visualisation, removal of polyps and tissue biopsy of the left colon. However, about two thirds of LS-associated colorectal cancers appear proximal to the left colon and may be missed with sigmoidoscopy (Coetzee 2013).

Colonoscopy allows for inspection of the entire colon and, if performed by a skilled professional, provides a sensitivity of up to 100% for detecting cancers and advanced adenomas (Coetzee 2013). There are no randomised controlled studies on routine colonoscopy screening (Coetzee 2013; Palomaki et al. 2009; Snowsill et al. 2014). However, observational studies (Level IIb evidence) exist that indicated a 62% reduction in incidence of colorectal cancer and 65% - 70% decrease in mortality (Palomaki et al. 2009). A South African study showed that colonoscopy screening produced better outcomes compared to no screening i.e. 11% vs 27% for colorectal cancer diagnosis and 2% vs 12% for death from colorectal cancer, respectively (Stupart et al. 2009). Colonoscopy is more invasive, requires sedation and bowel preparation, and has morbidity associated with this procedure (Coetzee 2013; Snowsill et al. 2014). The most common, serious adverse events related to colonoscopy in the general population are death 0.08/1000, perforation (3.3/1000) and bleeding (11.1/1000) (Palomaki et al. 2009).

Cost-effectiveness studies have recommended genetic testing as a strategy to identify high risk individuals for colonoscopy screening (Palomaki et al. 2009; Snowsill et al. 2014; Vasen et al. 2013). Germline testing is performed on blood and is diagnostic for LS. Partial reflex testing is done i.e. the result of a test done will determine whether another test will be performed and which test will be performed. Microsatellite Instability testing (MSI) or
Immunohistochemistry (IHC) was indicated as the preferred preliminary test to identify patients for genetic testing. IHC has the added advantage of directing germline testing to one of the four MMR genes (Palomaki et al. 2009; Snowsill et al. 2014; Vasen et al. 2013). MSI testing is labour intensive and expensive (Coetzee 2013). Performing $BRAF$ testing on tumours with absent $MLH1$ staining would identify patients that would not benefit from $MLH1$ gene sequencing and, consequently, significant cost savings could be implicated. (Palomaki et al. 2009; Snowsill et al. 2014; Vasen et al. 2013). Locally, however, $BRAF$ testing is technically not feasible (Voster, A: Division of Human Genetics: UCT, personal communication 2015). Recommendations on the most cost-effective germline testing have not yet been determined (Giardiello et al. 2014; Hampel 2010). Genetic testing counselling is recommended before and after undergoing germline testing, as well as follow-up counselling during colonoscopy screening sessions (Giardiello et al. 2014; Hampel 2010; palomaki et al 2009).

### 1.4.3 Cost effectiveness studies on screening strategies for Lynch Syndrome

Research to date, on cost-effectiveness of screening strategies for Lynch Syndrome, has focused on high income countries and therefore generalisability to the South African population is problematic.

A recent Health Technology Assessment included a systematic review of 32 cost-effectiveness studies (Snowsill et al. 2014). Most of the studies were conducted from a health provider perspective and the majority of studies were set in the United States of America. Studies in the review used different tests or combination of tests, and therefore it was not possible to identify the most frequently used tests. Many of the studies did not meet the criteria from the Drummond checklist (Drummond et al. 2005). The review failed to provide consistency with regards to the strategies or tests that would be most cost-effective.
All studies, however, concluded that screening for Lynch Syndrome compared to no screening was cost-effective (Snowsill et al. 2014).

Snowsill et al (2014) further conducted an economic evaluation comparing 8 screening strategies. Compared to no testing as the base case, MSI + $BRAF\, V006$ + genetic testing produced the lowest ICER. The more tests that were performed in sequence, the greater the specificity as well as the increased costs. Sensitivity analysis indicated that, even at low rates of acceptance of diagnostic tests and genetic counselling, Lynch Syndrome testing is cost-effective compared to no testing. Sensitivity analysis performed on widely varying the number of relatives per proband, including no relatives, found screening for Lynch Syndrome more cost-effective than no screening. The majority of the diagnosing cost for the cohort was due to diagnosing the probands, as opposed to diagnosing the relatives. Costs were driven by the number of tests taken. Long term, the most influential cost driver was the cost of colonoscopies and diagnostic costs did not significantly influence the variation in costs between strategies. Preventative costs outweighed the increased savings in cost from colorectal treatment (Snowsill et al. 2014).

Table 1 reflects the costs reported in various cost-effectiveness studies performed in different countries (Gross 2015). Total screening costs were around $2 242 to $3 345. One study was unusually high at a total cost of $6 312. Generally, the largest contributors towards the screening costs were the genetic testing for MLH1 and colonoscopy. Long-term the colonoscopy cost will be the main cost driver as the other costs are once-off costs. The lowest cost contributors were the genetic counselling costs and approaching relatives. The predictive tests for relatives were in all cases significantly lower than the genetic sequencing for MLH1 (identifying the mutation). This indicates the value of identifying a family mutation – i.e. relatives may be identified at a much lower cost for genetic testing and may benefit more from colonoscopy screening as they may not have cancer yet as opposed to the
proband who often present with cancer already. Furthermore, the cost of excluding a relative that tested negative for a mutation is far less than the cost of lifetime colonoscopy screening.

Table 1: Base case estimates of costs of routine testing and colonoscopy for Lynch Syndrome in patients with colorectal cancer and first degree relatives, in 2014 US $

<table>
<thead>
<tr>
<th>Study</th>
<th>Pre-test counselling</th>
<th>Post-test counselling</th>
<th>Counselling for gene sequencing</th>
<th>IHC</th>
<th>Gene sequencing for MLH1</th>
<th>Approaching relatives</th>
<th>Test for relative (predictive)*</th>
<th>Combined test and counselling</th>
<th>Colonoscopy unit cost</th>
<th>TOTAL COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mvundura et al. (2010) USA</td>
<td>22</td>
<td>106</td>
<td>194</td>
<td>290</td>
<td>899</td>
<td>350</td>
<td>61</td>
<td>441</td>
<td>1043</td>
<td>3345</td>
</tr>
<tr>
<td>% of total cost</td>
<td>0.66</td>
<td>3.17</td>
<td>5.80</td>
<td>8.67</td>
<td>26.88</td>
<td>10.46</td>
<td>1.82</td>
<td>13.18</td>
<td>31.18</td>
<td>100</td>
</tr>
<tr>
<td>Ladabaum et al (2011) USA</td>
<td>NR</td>
<td>112</td>
<td>198</td>
<td>300</td>
<td>942</td>
<td>118</td>
<td>492</td>
<td>610</td>
<td>690</td>
<td>2970</td>
</tr>
<tr>
<td>% of total cost</td>
<td>NR</td>
<td>3.77</td>
<td>6.67</td>
<td>10.10</td>
<td>31.72</td>
<td>3.97</td>
<td>16.57</td>
<td>20.54</td>
<td>23.23</td>
<td>100</td>
</tr>
<tr>
<td>% of total cost</td>
<td>1.12</td>
<td>6.07</td>
<td>0</td>
<td>8.21</td>
<td>52.81</td>
<td>3.43</td>
<td>15.74</td>
<td>19.18</td>
<td>9.19</td>
<td>100</td>
</tr>
<tr>
<td>Snowsill et al (2014; 2015) UK</td>
<td>0</td>
<td>0</td>
<td>103</td>
<td>366</td>
<td>714</td>
<td>103</td>
<td>265</td>
<td>368</td>
<td>911</td>
<td>2565</td>
</tr>
<tr>
<td>% of total cost</td>
<td>0</td>
<td>0</td>
<td>4.02</td>
<td>14.27</td>
<td>27.84</td>
<td>4.02</td>
<td>10.33</td>
<td>14.35</td>
<td>35.52</td>
<td>100</td>
</tr>
<tr>
<td>Severin et al (2014) Germany</td>
<td>57</td>
<td>161</td>
<td>0</td>
<td>166</td>
<td>5268*</td>
<td>57</td>
<td>281</td>
<td>338</td>
<td>265</td>
<td>6312</td>
</tr>
<tr>
<td>% of total cost</td>
<td>0.90</td>
<td>2.55</td>
<td>0</td>
<td>2.63</td>
<td>83.46</td>
<td>0.90</td>
<td>4.45</td>
<td>5.35</td>
<td>4.20</td>
<td>100</td>
</tr>
<tr>
<td>Barzi et al (2015) USA</td>
<td>NR</td>
<td>112</td>
<td>198</td>
<td>300</td>
<td>942</td>
<td>118</td>
<td>492</td>
<td>610</td>
<td>690</td>
<td>2970</td>
</tr>
<tr>
<td>% of total cost</td>
<td>NR</td>
<td>3.77</td>
<td>6.67</td>
<td>10.10</td>
<td>31.72</td>
<td>3.97</td>
<td>16.57</td>
<td>20.54</td>
<td>23.23</td>
<td>100</td>
</tr>
</tbody>
</table>

NR: Not reported  * Not added to total (included in combined counselling and test)
# Genetic testing costs is not higher in Germany. The German reimbursement for gene sequencing is an outlier.


2. Aims, objectives and conceptual framework

2.1 Aim

The aim of the study is to provide evidence of the relative cost of two screening options for colorectal cancer for persons with Lynch Syndrome for policy-making purposes in the public sector. Thus, costs for colonoscopy screening only (Strategy 1) will be compared with costs of conducting genetic testing for Lynch Syndrome followed by colonoscopy screening for the individuals that tested positive for Lynch Syndrome (Strategy 2).
2.2 Objectives

1. To estimate the unit cost of colonoscopy.

2. To estimate the weighted average unit cost of identifying the MMR gene mutation in patients with colorectal cancer.

3. To estimate the weighted average unit cost of genetic testing for relatives of the proband.

4. To use these unit costs to estimate and compare the total cost of screening for the two screening strategies for the same cohort of individuals.

2.3 Conceptual framework

Unit costs for colonoscopy and genetic testing will be estimated according to the utilisation patterns at the health facility and the expenditure incurred. Unit costs for colonoscopy will be estimated by dividing the total annual cost of colonoscopy by the number of colonoscopies performed per annum. Unit costs for genetic testing will be estimated by calculating the weighted average unit cost for genetic testing where the weighting will be estimated according to the proportion of patients that required a particular test or series of tests. These unit costs will be applied to the actual utilisation of potential LS patients (probands) and the total number of colonoscopies estimated per individual per lifetime per Strategy option in order to estimate the total costs for Strategy 1 and 2. Table 2 presents the conceptual framework for Strategy 1 and 2.
### Table 2: Conceptual framework for estimating costs per screening strategy

<table>
<thead>
<tr>
<th>STRATEGY 1</th>
<th>STRATEGY 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colonoscopy screening only</strong></td>
<td><strong>Genetic testing and colonoscopy screening for positively tested individuals</strong></td>
</tr>
<tr>
<td><strong>1. Unit Cost:</strong> To estimate the unit cost of colonoscopy.</td>
<td><strong>1. Unit Cost A:</strong> To estimate the unit cost of colonoscopy.</td>
</tr>
<tr>
<td><strong>2. Utilisation:</strong> To estimate the total number of colonoscopies required per lifetime for all individuals eligible for colonoscopy as per Strategy 1.</td>
<td><strong>2. Utilisation A:</strong> To estimate the total number of colonoscopies required per lifetime for all individuals eligible for colonoscopy as per Strategy 2.</td>
</tr>
<tr>
<td><strong>3. Total cost = Unit cost x Utilisation:</strong> To estimate the total cost of screening for Strategy 1 (i.e. unit cost of colonoscopy x total number of colonoscopies required).</td>
<td><strong>3. Unit Cost B:</strong> To estimate the weighted average unit cost for:</td>
</tr>
<tr>
<td></td>
<td>- genetic testing for diagnosing a proband</td>
</tr>
<tr>
<td></td>
<td>- genetic testing for diagnosing a relative</td>
</tr>
<tr>
<td></td>
<td>- genetic counselling</td>
</tr>
<tr>
<td></td>
<td><strong>4. Utilisation B:</strong> To estimate the total number of tests and genetic counselling sessions required.</td>
</tr>
<tr>
<td></td>
<td><strong>5. Total cost = (Unit cost A x Utilization A) + (Unit cost B x Utilisation B):</strong> To estimate the total cost of screening for Strategy 2 (i.e. unit cost of colonoscopy x total number of colonoscopies required + unit cost of genetic testing x total number of tests + unit cost of genetic counselling x total number of counselling sessions required).</td>
</tr>
</tbody>
</table>

6. To compare the total cost of Strategy 1 and 2

### 3. Method

#### 3.1 Study design

The study design will be a comparative cost analysis, focusing on the collection of primary cost data, and will be conducted from a service provider perspective. A predominantly micro-costing, ingredient-based approach will be followed. The most relevant costs will be related to the resources used to perform colonoscopy and genetic testing. Costs of resources will be presented in 2016 South African rands and US dollars.
3.2 Setting and population

The study will be undertaken at Groote Schuur hospital (GSH) in Observatory in the Western Cape, South Africa. GSH is a public sector, tertiary, academic hospital that provides sub-specialist level care. In South Africa, approximately 80% of the population seeks health care in the public sector (Department of Health 2014) and patients in this study were predominantly from the Western Cape and Northern Cape provinces. The colonoscopy service was provided by GSH while the genetic testing service for testing for Lynch Syndrome was provided on a research basis by the Human Genetics Research Unit in the Division of Human Genetics at the University of Cape Town (Ramesar, R: Division of Human Genetics: UCT, personal communication 2015).

Patients on the UCT Lynch Syndrome DNA database (Ethics approval: HREC REF: 217/2010) will be considered in the study (Voster, A: Division of Human Genetics: UCT, personal communication 2015). The patients (probands) on this database were selected if they met the Revised Bethesda Criteria after presenting with colorectal cancer or other LS-related cancer. Due to advancements in genetic testing over the years, analysis of the data will be restricted to probands tested between 01 November 2014 and 30 October 2015 in order to ensure that the latest test methods are assessed to estimate costs. Probands and their relatives will be analysed according to their age, relationship to the proband, alive status, tests performed, results of tests and surgical procedures performed. Probands and their first degree relatives (parents, children and siblings) that are eligible for colonoscopy screening will be considered for inclusion in the cost assessment. Persons that would not be eligible for colonoscopy screening would be excluded from the study, such as spouses, spouse’s family, deceased persons, persons under 25 years and over 60 years and persons that would not have colonoscopy screening (e.g. patients who had total colectomies). See Part D: Appendices: S1 Fig. and S2 Fig.)
3.3 Screening strategies

The screening strategies considered were based on the services currently available at GSH and the collaboration with the Division of Human Genetics at UCT. Probands and first degree relatives will be considered as per the proposed protocol and current services available (Ramesar, R: Division of Human Genetics: UCT, personal communication 2015). LS-associated mutations have an autosomal dominant pattern and, therefore, there is a 50% chance that the mutation will be passed on to the first degree relative.

Both screening strategies will be applied to the same cohort (see section 3.2 for inclusion and exclusion criteria) and total cost per strategy will be estimated. Thus, probands on the DNA database that were tested between 01 November 2014 and 30 October 2015, and their first degree relatives will be evaluated according to the two strategies below (See Part D: Appendices S1 Fig and S2 Fig):

- Strategy 1 will involve estimating the cost for intensive colonoscopy screening for probands and their first degree relatives that are eligible for screening.

- Strategy 2 will involve estimating the cost for genetic testing for all probands and the first degree relatives of LS-positive probands plus the cost of intensive colonoscopy screening for all individuals with a genetic test-confirmed diagnosis of Lynch Syndrome.

Intensive colonoscopy screening involves colonoscopy screening biennially for patients under 30 years old and annually for individuals aged 30 years and older up to 60 years; thereafter colonoscopy will be every ten years (Voster, A: Division of Human Genetics: UCT, personal communication 2015). Individuals that tested negative on germline testing will be managed as per the general population i.e. colonoscopy every ten years after the age of 50 years. Taking into account the ages of the probands and their first degree relatives, the total lifetime number of colonoscopies for the two strategies will be estimated and costed.
Colonoscopy is a 30 to 60 minutes procedure performed in a dedicated, equipped room (Algar: GSH, personal communication 2015). A colonoscope is inserted into the rectum, through the colon and as far as the caecum. Prior to the procedure, patients are given a special cleansing preparation to clear the bowel. Sedatives may be given for pain control and to relax the patient. An intravenous cannula is prepared in the event that patients may require intravenous fluid or medication. The patient’s heart rhythm and blood pressure is monitored continuously. Post-colonoscopy, the patient is kept in an observation area for 1 to 2 hours. In the event of an incomplete colonoscopy, the procedure may be repeated at a later stage. (Algar: GSH, personal communication 2015)

Genetic testing to diagnose Lynch Syndrome is complex due to the genetic heterogeneity and the preliminary screening tests that can be performed prior to genetic testing (Hampel 2010). The reflex genetic testing procedure followed by the Division of Human Genetics at UCT for diagnosing Lynch Syndrome was applied in this study. (Voster: Human Genetics: UCT, personal communication 2015). Where possible, immunohistochemistry (IHC) testing is routinely performed as a first line preliminary screening test (Coetzee 2013). Negative staining of IHC testing i.e. absence of an MMR gene product, suggests a high risk for Lynch Syndrome. If the IHC shows presence of all genes, but a strong clinical suspicion exits, the patient will be offered MSI testing. MSI testing is expensive, labour intensive, time consuming and requires a skilled geneticist and, therefore, is only provided on request (Coetzee 2013). IHC and MSI are provided by the National Health Laboratory Services (NHLS). Germline testing is provided via NHLS and Division of Human Genetics Department at UCT (Voster: Human Genetics: UCT, personal communication 2015). All patients (probands) on the database undergo genetic testing. Genetic testing involves DNA isolation from whole blood, followed by testing for the 5 common founder mutations. A positive result for a founder mutation would be followed by Multiplex Ligation-dependent Probe Amplification (MLPA) analysis or Sanger sequencing on a different day and different
blood sample for quality assurance (confirmation) purposes. In the case of a known mutation, that is not a common founder mutation, Sanger sequencing would be done, and this would be repeated on a separate day on a separate blood sample for quality assurance purposes. On identification of the MMR gene mutation in the index patient, the relatives would be offered germline testing for the identified MMR mutation. \textit{BRAF V600E} is not offered due to its technical complexity. Individuals identified for genetic testing should receive genetic counselling by a trained genetic counsellor prior to and post undergoing genetic testing, as well as during colonoscopy screening. In addition, informed consent for genetic testing is a prerequisite to genetic testing. All positive probands and their first degree relatives would be offered intensive colonoscopy screening (Voster: Human Genetics: UCT, personal communication 2015; Hampel 2010).

In summary, IHC is performed on probands with suitable colon tissue available for this test. All probands would receive screening genetic tests i.e. the Common Founder test or a Sequencing test for those with a known family mutation that is not a founder mutation. Only probands with positive screening tests would receive quality assurance / confirmatory tests i.e. a digestive test and / or another sequencing test. See Part D: Appendices: S3 Fig for the flow diagram of tests performed.

\section*{3.4 Cost analysis}

Costs are the value of the resources required to provide a particular service (Gray et al. 2012). The costs for performing a colonoscopy and genetic testing will be identified, quantified (measured) and valued.

Table 3 displays a summary of the categories of costs / resources that will be considered, together with the methods that will be used to collect, measure and value these costs.
### Table 3: Identification, measurement and valuation of costs

<table>
<thead>
<tr>
<th>TYPE OF COST</th>
<th>IDENTIFICATION</th>
<th>MEASUREMENT</th>
<th>VALUATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Capital cost</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Building</td>
<td>Colonoscopy room, recovery, consulting room, waiting room, toilet, prep room, laboratory space, laboratory extraction room, etc.</td>
<td>Proportion of square metres floor space used or proportion of activities</td>
<td>Observation and WCGH: Depart of Public Works architectural drawings</td>
</tr>
<tr>
<td>Equipment</td>
<td>Medical &amp; genetic testing equipment, heart monitor, colonoscope, processor, gel documentation, workstation, computer, thermal cycler, centrifuge, refrigerators, other laboratory equipment</td>
<td>Proportion of lifetime use or number of uses / activities.</td>
<td>Observation and staff interviews; Asset report</td>
</tr>
<tr>
<td>Furniture</td>
<td>Tables, chairs, cabinets, examination beds, stools, bed steps, etc.</td>
<td>Proportion of lifetime use</td>
<td>Observation and staff interviews; Asset report</td>
</tr>
<tr>
<td><strong>Recurrent cost</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personnel</td>
<td>Administration, clinician, nurses, managers, genetic counsellors, laboratory technicians, medical technician, general assistants</td>
<td>Proportion of working hours spent on colonoscopy, genetic testing or counselling</td>
<td>Observation and staff interviews</td>
</tr>
<tr>
<td>Overheads and Maintenance</td>
<td>Overhead (electricity, telephone, stationery, water, laundry, etc.). Maintenance of equipment, waste disposal, housekeeping</td>
<td>Proportion of personnel time; proportion of floor space; 8% markup for maintenance</td>
<td>Observation, staff interviews</td>
</tr>
<tr>
<td>Consumables</td>
<td>Needles, syringes, gloves, swabs, specimen jars, cleaning supplies, disinfectants, aprons, stationery, polypectomy snares, forceps, needle injector, plates</td>
<td>Shared -proportion of patients</td>
<td>Procurement records, observation, patient records</td>
</tr>
<tr>
<td>Medicines</td>
<td>Sedation, premed, bowel preparation, IVI fluids, etc.</td>
<td>Shared -proportion of patients</td>
<td>Observation and patient records</td>
</tr>
<tr>
<td>Laboratory tests</td>
<td>Laboratory tests, genetic tests, DNA isolation, MSI test, IHC test, disinfectants, reagents, etc.</td>
<td>Shared -proportion of patients</td>
<td>Procurement records, observation and patient records</td>
</tr>
</tbody>
</table>

---

**Notes:**
- BAS: Basic Accounting System; CSIR: Council for Scientific and Industrial Research; DBSA: The Development Bank of South Africa; DPSA- COLA: Department of Public Service and Administration Cost-of-Living Adjustments; GSH: Groote Schuur hospital; DPSA- COLA; GSH personnel report
- IHC: Immunohistochemistry; MSI: Microsatellite Instability; NDOH: National Department of Health; NHLS: National Health Laboratory Services; PERSAL: Personnel and Salary System; WCGH: Western Cape Government – Health; WCGH SCM Supply Chain Management; UCT: University of Cape Town

**PART A: Protocol**
Costs will be estimated in terms of recurrent costs and capital costs. Recurrent costs will generally be estimated by using an ingredient-based approach i.e. costs will be calculated by multiplying unit costs by the quantities or proportion of resources used. Any item used for longer than one year will be considered a capital cost (Gray et al. 2012). The equivalent annual cost of a capital item will be estimated by annuitizing the initial capital expenditure using a discount rate of 3% (Glick et al. 2007; Mangham 2009; Drummond et al. 2005). Useful life-years for capital items will be assumed as follows - buildings: 30 years; major equipment: 5 to 10 years; furniture: 10 years; vehicles: 3 – 5 years and small equipment: 1 – 5 years; training: 10 years (Drummond et al. 2005; Somda et al. 2007). An 8% mark-up is the standard included in Department of Health contracts for the maintenance of equipment and will be considered for calculating maintenance costs of equipment. (Rademeyer: Deputy Director: WCGH Department of public Works, personal communication 2015).

For shared costs e.g. overheads, departments or resources that directly affect the service to the patient will be identified. A unit of output e.g. number of hours for staff costs, square meters floor space for housekeeping, etc. will be determined and allocation of costs will be done in terms of the proportion of units of outputs used to provide the service. (Drummond et al. 2005; Gray et al. 2012).

For personnel costs, a unit cost (cost per minute) for the different cadre of staff will be determined by dividing the annual total cost to company by the annual total working minutes of the staff member.

Major adverse events are rare (Palomaki et al. 2009) and will be excluded from the study. Grosse (2015) reported in a review that differences in assumptions regarding complications as well as excluding complications had little influence on incremental cost effectiveness ratios (ICERS).
Data from colonoscopies performed on the study cohort indicated that approximately 6% of colonoscopies may require repeat colonoscopies (Algar: GSH, personal communication 2015). Repeat colonoscopies will be included in the average unit cost for colonoscopy.

The cost of genetic testing may vary from patient to patient depending on the type of test and the number of tests that were conducted on the patient. The unit cost for genetic testing per proband or first degree relative will, therefore, be estimated by calculating the weighted average cost for genetic testing where the weighting will be estimated according to the estimated proportion of patients that required a particular test or series of tests. Costs for tests performed by the NHLS (e.g. IHC and MSI) will be obtained from expenditure reports from Groote Schuur hospital or from the NHLS price lists.

Discount rate should be applied for programmes with differential timing of cost outlays. A discount rate of 3%, consistent with existing literature, was used as per the recommendations by Drummond et al, 2005. The South African Department of Health recommends that undiscounted costs should be reported on as well as a baseline annual discount rate of 5% (Department of Health; Government Gazette No. 36118). Thus, sensitivity analysis was done on discount rates of 0% and 5%.

The unit cost data of colonoscopy and genetic testing, as well as the total lifetime number of colonoscopies required will be used to estimate the total cost for the cohort for Strategy 1 and Strategy 2.

Data will be collected in 2015 by interviewing staff, folder reviews and observing activities. Costs will also be obtained from expenditure records, tender documents, purchase contracts, service agreements and the Department of Health (DOH) financial year 2014/2015 expenditure records and UCT 2015 expenditure and financial records. DOH costs will be used to value resources and where not available, market prices will be used. In the case of donated / volunteer resources, costs of these resources will be valued in terms of DOH costs,
and if not available, the market prices (or actual cost) will be used (Drummond et al. 2005; Gray et al. 2012). Examples of data collection and analysis tools are shown in the appendices (See part D: Appendices: S1 Table to S4 Table).

3.5 Sensitivity analysis

Uncertainties that would be most relevant in the study include the number of first degree relatives that would test positive and the number of colonoscopies required. The number of colonoscopies would depend on adherence to colonoscopy screening, and the number of relatives that tested positive. Literature reported adherence rates ranging from 79% to 88% (Grosse et al. 2015). However, a study conducted in South Africa found an adherence rate as low as 25% in LS-diagnosed persons (Bruwer et al. 2013). Therefore, adherence rates of 25%, 50%, 75% and 85% will be analysed. Positivity rates of 39% to 50% were reported in literature (Grasse et al. 2015). However, around 27% of the relatives on the DNA database tested positive. Sensitivity analysis will, therefore, be conducted on positivity rates of 30%, 45% and 50%. Drummond et al. 2005 recommended that sensitivity analysis be performed on discount rates used commonly as well as no discount rate. Thus, discount rate of 5% and 0% will be considered in the sensitivity analysis as per the recommendations in the South African Department of Health guidelines for pharmaco-economic submissions (Department of Health; Government Gazette No. 36118).
3.6 Assumptions

The following assumptions will be made:

- Mortality rates as per the general population were applied to both strategies. Risks of cancers that are part of the LS spectrum in this study population have not been published. The costs, therefore, may be overestimated. This exclusion is not expected to affect the direction of the hypothesis as the incidence of other cancers would be higher in the genetic tested LS-diagnosed group (Strategy 2) and thus potential increased mortality rate in this group.

- All probands and first degree relatives of positive probands will be willing to undergo genetic testing.

4. Data analysis and management

Costs will be estimated and presented as per the objectives in section 2.2: Aims and Objectives and section 3.4: Cost analysis. Data will be captured and analysed using Microsoft Excel®; and stored in password protected folders. Part D: Appendices: S1 Table to S4 Table shows examples of tools for data collection and calculations of costs for personnel, buildings, equipment and consumables; and Part D: Appendices: pages 3 – 5 illustrate the assessment of eligible individuals for colonoscopies and genetic testing. See section 2.3: Conceptual framework for estimation of unit costs and total costs for colonoscopy and genetic testing. Completeness and accuracy of the data is the responsibility of the researcher. A data back-up system will be maintained. Data from the templates will be recorded directly onto the database. The data will be cleaned and once all queries have been addressed, the database will be locked.
5. Ethical considerations

5.1 Potential benefits and risks

This study poses no potential risk or harm to the participant. This study is unlikely to benefit the individual participants directly. Important indirect benefits will be that the information may direct future resources towards the management of Lynch Syndrome in terms of genetic testing and colonoscopy screening, and prevention of inappropriate exposure to invasive colonoscopy procedures.

5.2 Autonomy and informed consent

Informed consent will be obtained from staff and informants that assist with information and access to documents related to costs. Informants and staff will be made aware that participation and withdrawal from the study is voluntary.

5.3 Confidentiality

Privacy and confidentiality will be assured. Information will be captured under unique identifiers and no names will appear on forms or in the database. No personal identifiers will be used in the analysis or appear in any publication or report. All electronic data will be password protected and accessible only to the study team. Paper forms will be stored in a locked cupboard.

5.4 Ethical approval

This protocol will be submitted to the University of Cape Town Human Research Ethics Committee (UCT HREC) for approval. The protocol will also be submitted to the relevant Provincial DOH authorities for review and permission to implement the study in areas of their jurisdiction.
6. Publication and dissemination

The study will be submitted for the Masters in Public Health: Health Economics degree. The findings of the study will also be submitted to the relevant Department of Health officials in the Western Cape, Division of Human Genetics: UCT, Groote Schuur hospital and persons that participated in the study. A manuscript will be drafted for publication.

7. Logistics

The study will be conducted over a 12 month period. The activities and time lines are shown in Table 4

Table 4: Study time lines

<table>
<thead>
<tr>
<th>Activity</th>
<th>Nov</th>
<th>Dec</th>
<th>Jan</th>
<th>Feb</th>
<th>Mar</th>
<th>Apr</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>Aug</th>
<th>Sept</th>
<th>Oct</th>
<th>Nov</th>
<th>Dec-March</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finalise protocol</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obtain approval: GSH, DOH, Ethics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finalise data capture forms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect data: Observation &amp; interview</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collect data: Review records, tender docs, etc.</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capture data on database</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analyse &amp; clean data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Write up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Complete dissertation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Submission</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8. Budget

The study will be self-funded.
References


PART A: Protocol


Somda, Z.C., Meltzer, M.I., Perry, H.N. 2007. SurvCost 1.0: a manual to assist country and
district public health officials in estimating the cost of the implementation of IDSRS. CDCP.
Department of Health and Human Services. USA.

Wentink, M.Q., Räkers, M., 2010. Incidence and histological features of colorectal cancer in
the Northern Cape Province, South Africa. SAJS. 48:4, 109-113.
PART B: STRUCTURED LITERATURE REVIEW

A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a tertiary hospital, South Africa
1. Introduction

A comparative cost analysis will be conducted for screening options for colorectal cancer in Lynch Syndrome (LS), with a focus on the available options for South Africa. Objectives of this literature review will, thus, seek to inform on the following:

- An overview of LS and its impact within the South African context.
- Effective diagnosing and screening options for colorectal cancer in LS.
- Economic evaluation and cost implications of screening strategies for colorectal cancer in LS.
- Economic evaluation methodology for assessing costs, with a focus on screening strategies for colorectal cancer in LS.

This literature review, firstly, describes key aspects of Lynch Syndrome (LS) in terms of incidence, risks and clinical features of the disease in order to inform on the impact of LS on society. The next section briefly describes screening options for colorectal cancer in LS and this is followed by economic evaluations conducted on various screening strategies. Lastly, approaches to economic evaluations and cost analysis for priority setting and resource allocation in public health are discussed. The review concludes with describing the existing gaps in literature with regards to the purpose for this study.

A search filter was used to identify literature for in PUBMED, Google Scholar and the Cochrane Collaboration database. Search terms were based on search terms used in evidence-based guidelines and systematic literature reviews (Palomaki et al. 2009; Giardello et al. 2014; Snowsill et al. 2014). Search terms included Lynch Syndrome, health economics, cost analysis, cost-effectiveness, genomics, genetic testing, hereditary cancer, colorectal cancer, mismatch repair, MMR, HNPCC, hereditary nonpolyposis colorectal cancer, colorectal neoplasm, colonoscopy and colorectal cancer surveillance. Due to
advancements in technology and management of Lynch Syndrome, publications retrieved on these subjects were restricted to periods after 2004 (Palomaki et al. 2009; Giardello et al. 2014). The language filter was restricted to English publications. Four evidence-based guidelines (Palomaki et al. 2009; Giardello et al. 2014; EGAPP 2009; Vasen et al 2013) and one Health Technology Assessment (HTA) (Snowsill et al. 2014) formed the bases of the review. The information across these documents was generally consistent in terms of prognosis, risks, guidelines and similar studies were cited. Stupart et al (2009) provided observational study data on outcomes of colonoscopy surveillance for the population of this study. All studies on outcomes of colonoscopy were observational. Information on costs was contained in observational studies on cost-effectiveness; and these costs were summarised in a review by Grosse (2015) and the HTA (Snowsill et al 2014). Adherence data were obtained from two studies conducted in South Africa (Bruwer et al 2013; Bruwer et al 2013). Information on economic and cost analysis methodology were derived predominantly from Drummond et al (2005) and Gray et al (2012) and published studies on cost analysis of health programmes (Subramanian et al 2010; Sinanovic et al 2006; Sinanovic et al 2003). Around 14 studies conducted on Lynch Syndrome in South Africa were retrieved. However, these studies involved the clinical aspects of the disease (Stupart et al 2009; Wentwink et al 2010; Hitchins et al 2011; Hameed et al 2005); quality of a mobile colonoscopy service (Anderson et al 2005) and adherence and uptake rates (Bruwer et al 2013; Bruwer et al 2013). No local study involved the economic aspects related to providing a colonoscopy screening service for Lynch Syndrome individuals. Grey literature such as policy documents (National Department of Health: Sub-directorate Human Genetics, 2000), standard operating procedures for genetic testing (Division of Human Genetics, 2015) and colonoscopy (GSH Gastroenterology Department, 2011), as well as draft protocol documents (GSH Gastroenterology Department, 2015) were
reviewed. Protocols on guidelines for the genetic testing procedures were not finalised at the time of the study. Thus, actual procedures, based on the draft protocols and observation at the time of the study, were assessed.

2. Update on Lynch Syndrome

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) defined LS as an autosomal dominant disorder that predisposes individuals to certain cancers, with colorectal cancer as a major clinical consequence (Palomaki et al. 2009). Individuals with LS may or may not have cancer. EGAPP recommended that the previously used term, hereditary nonpolyposis colorectal cancer (HNPCC), be abandoned (Palomaki et al. 2009). LS is due to mutations in the mismatch repair (MMR) genes and persons with this disorder display high rates of multiple primary tumours, have an early age of onset of cancer and generally have an absence of typical risk factors (Vasen et al. 2013).

Aldred Warthin first described Lynch Syndrome as far back as 1913 (Giardiello et al. 2014; Wolf et al. 2013; Lynch et al. 2015). In 1966, Dr Henry T Lynch provided further insight when he described families with this hereditary colorectal predisposition. He found that 60% to 80% of these colorectal tumours were located in the proximal colon compared to about 30% in sporadic cancer. High rates of synchronous and metachronous colorectal cancer with a Chrons-like pattern were also observed. Other LS-associated include endometrial cancer, cancers of the small bowel, stomach, hepatobiliary tract, pancrease, ureter, ovaries, renal pelvis, breast, prostate, sebaceous glands and glioblastoma, amongst others (Giardiello et al. 2014; Lynch et al. 2015). Diagnosis of LS has progressed over the past two decades to include differential diagnosing (family history, clinical phenotype, histopathological characteristics) and definitive diagnosing (germline testing). Since 2000,
over a period of 12 years, commercial genetic testing became available for the four MMR
genes plus *EPCAM*. With the recent introduction of next-generation sequencing panels,
additional genes are likely to be associated with LS (Giardiello et al. 2014; Wolf et al.
2013; Lynch et al. 2015).

3. Aetiology

The underlying deoxyribonucleic acid (DNA) mismatch repair (MMR) gene defect was
discovered in the early 1990’s (Palomaki et al. 2009; Giardiello et al. 2014; Wolf et al.
2013). Mutations were found in one of the MMR genes; namely, *MLH1, MSH2, MSH6* or
*PSM2*. Up to 90% of mutations in LS are found in *MLH1* and *MSH2*, and around 10% of
mutations in *MSH6*. More recently, deletions of the 3’ end of *EPCAM* (directly upstream
of the *MSH2* gene) were reported and these deletions resulted in epigenetic
hypermethylation of the *MSH2* promoter, thereby resulting in Lynch Syndrome. MMR
genes produce MMR proteins involved in detecting and correcting DNA replication errors.
A defect in the MMR system leads to loss of function of the entire MMR complex and an
inability to restore base-base mismatches and small insertions and deletions in DNA
sequences. This results in an accelerated accumulation of genetic mutations which often
progresses to carcinogenesis. Although mutations occur all over the genome, repetitive
DNA sequences such as microsatellites are particularly prone to these mutations. This
phenomenon of abnormal patterns of microsatellite repeats is referred to as microsatellite
instability (MSI). MSI occurs in more than 90% colorectal cancers in LS and together with
age of onset of disease and familial findings, MSI is a strong predictor of LS (Palomaki et
Thus far, 19 different mutations in the MMR genes have been identified (as at Nov 2015) in the 62 families on the DNA database (HREC: REF: 217/2010) that formed part of our study. Of these, five common founder mutations have been associated with our cohort. The commonest mutation found in about 30% of these individuals was $MLH1C12528T$.

4. Prevalence and risk

Globally, colorectal cancer is noted as the third most common cancer and cause of cancer-related deaths. It is estimated that the global annual incidence of colorectal cancer is more than 1 million (Graham et al. 2012; Wentwink et al. 2010). In 2008, colorectal cancer accounted for more than 600,000 deaths, of which 70% occurred in low and middle income countries. The most common cause of hereditary colorectal cancer is Lynch Syndrome which accounts for approx. 3% to 5% of all colorectal cancers (Graham et al. 2012; Vasen et al. 2013; Snowsill et al. 2014).

In South Africa, colorectal cancer is the fifth most common cancer, with approximately 4697 new cases and 3138 deaths reported in 2012 (National Health Laboratory Services: Globocan, 2015). Just over half of the new cases diagnosed and 41% of deaths occurred in individuals younger than 65 years of age (National Health Laboratory Services: Globocan, 2015). Though adequate recording of colorectal cancer incidence exists in South Africa, estimates for LS are lacking as a formal reporting system for Lynch Syndrome does not exist (Coetzee et al. 2013). Other than the LS register (DNA database HREC: REF: 217/2010) maintained by the University of Cape Town (UCT), there are very few, if any hereditary colorectal cancer registries in South Africa (Coetzee et al. 2013). With information from this register, Vergouwe, et al (2013) showed that inherited cancers
formed a three times bigger proportion of the total burden of colorectal cancer in a low-prevalence area for colorectal cancer compared to high prevalence areas i.e. 10.5% vs 3%. He postulated that in low incidence areas such as South Africa, the prevalence of inherited cancers may be higher than the established values in the literature (Vergouwe et al, 2013).

The risks of developing cancers associated with LS are continuing to evolve with the increased application of germline testing and these risks are highly MMR gene mutation and sex dependent (Bonadona et al. 2011; Giardiello et al 2014). A person with LS has a 25% to 75% risk of colorectal cancer i.e. up to 1 in 3 people will develop colorectal cancer before the age of 70 years if there is no intervention. Though more recent studies have presented lower lifetime risks of 50%, this is still ten times higher than risks in the general population. Evidence suggests that MLH1 and MSH2 are the most widely distributed and has the highest risk of cancer. An evidence review performed by EGAPP (2009) reported that there is limited data that implies distributions of mutations of 32% in MLH1, 38% in MSH2, 14% in MSH6 and 15% in PMS2. Snowsill et al. (2014) reported distributions of mutations based on 12 624 observations internationally; i.e. 39% in MHL1, 34% in MSH2, 20% in MSH6 and 8% in PMS2. This information, however, is context specific and bias in terms of local referral guidelines. In the UCT cohort that will be used in this study, MHL1 and MSH2 mutations were identified, but to date no MSH6, PMS2 and EPGAM mutations have been identified (Voster, A: Division of Human Genetics: UCT, personal communication 2015). The highest risks, in the region of 40% to 70%, were associated with individuals with MLH1 and MSH2 mutations (Bonadona et al. 2011; Giardiello et al. 2014). Lower risks were reported for MSH6 (10% - 22%) and PMS2 (15% - 20%). For men the risk of colorectal cancer was reported to be higher than for women i.e. 38% - 45% compared 31% - 35% (Bonadona et al. 2011; Giardiello et al. 2014). The MMR mutation distributions for the UCT DNA database cohort indicated a population that falls in the
highest risk category (predominantly $MLH1$ & $MSH2$), reinforcing the need for an effective screening programme. Currently, due to resource constraints, the Division of Human Genetics: UCT appropriately directed their genetic testing strategy predominantly on the common founder mutations in the $MLH1$ and $MSH2$ genes.

In LS, the mean age at diagnosis of colorectal cancer is 41 to 66 years, whereas for the general population diagnosis is usually at around 69 years (Giardiello et al 2014; Bonadona et al. 2011; Cohen et al. 2014; Snowsill et al. 2014)). Furthermore, about half of colorectal cancer cases develop before the age of 50 years in LS compared to 10% in the general population. The estimated cumulative risks in carriers began to increase from the age 30 years irrespective of the gene mutation involved. Also, approximately 15% - 20% of cancer survivors with Lynch Syndrome will develop a second colorectal cancer within 10 years, 40% - 50% within 20 years and >60% within 30 years. Progression of adenoma to carcinoma is accelerated in individuals with Lynch Syndrome compared to sporadic and familial colorectal cancers. In Lynch Syndrome polyps may progress to carcinoma within 2 to 3 years as opposed to 8 to >10 years in the general population (Giardiello et al 2014; Bonadona et al. 2011; Cohen et al. 2014; Snowsill et al 2014). It is clear from the evidence that individuals affected by this disorder are in the age range of persons that are usually economically active and support families and, thus, the impact of this disorder stretches wider than just the individual. Delaying or preventing the onset of cancer would, therefore, be desirable. Furthermore, due to the autosomal dominant nature of the disorder, if one parent has an MMR mutation, this mutation will be inherited by his or her child i.e. the first degree relative (FDR) has a 50% chance of having LS (Snowsill et al. 2014). A first degree relative is a parent, child or sibling. EGAPP noted that there is limited, but promising evidence that testing / screening a patient for LS will impact on clinical management that will significantly improve health-related outcomes (Palomaki et al.
Risk-reducing strategies may be offered such as early treatment of cancer, surgical interventions and cascade testing of relatives (Palomaki et al. 2009).

5. Diagnosing Lynch Syndrome

Diagnosing individuals with LS is key in the management of this disorder as these individuals can benefit from life-saving intensive cancer screening (Giardiello et al. 2014; Vasen et al 2013; Lynch et al 2015). It is believed that LS is underdiagnosed due to the intricacy of diagnostic strategies, and thus, poor implementation of these strategies (Vasen et al. 2013). Accessibility and lack of awareness amongst the general population further contributed to the underdiagnosing of LS (Vasen et al. 2013).

Technology for identifying LS is rapidly advancing, making it problematic to compare earlier studies and recent studies (Snowsill et al. 2014). Furthermore, heterogeneity amongst the studies and robustness of testing methods make pooling of data difficult. A number of strategies exist for diagnosing LS (Giardielloe et al 2014; Lynch et al 2015; Snowsill et al 2014; Vasen et al 2013). Differential diagnosis includes family history, histopathology and prediction models. Definitive diagnosis involves identification of the MMR mutation by genetic testing (Lynch et al. 2015). Low specificity of tests would result in a high number of false positives and individuals may be informed that they have LS when they do not; and as a consequence be exposed to invasive and potentially hazardous procedures unnecessarily. Low sensitivity would result in a high number of missed cases (Snowsill et al. 2014).
5.1 Family history and computational models

Family history is still considered an important element in assessing risk in the general population (Palomaki et al. 2009; Giardiello et al. 2014; Vasen et al. 2013). The Amsterdam criteria exhibited a relatively low sensitivity of 22% and a specificity of 98% for diagnosing LS. The Revised Bethesda Criteria (see Table 1), also, did not deliver the necessary sensitivity (82%) and specificity (77%) as a preliminary screening test (Polomaki et al. 2009; Giardiello et al. 2014). Challenges with consistency in collecting information, time taken to collect information and accuracy of information collected contributed to the recommendation by EGAPP to remove family history as a preliminary test for patients newly diagnosed with colorectal cancer (Palomaki et al. 2009).

Table 1: Revised Bethesda Criteria

<table>
<thead>
<tr>
<th>1. Colorectal cancer diagnosed at younger than 50 years.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Presence of synchronous or metachronous colorectal cancer or other LS-associated tumours#.</td>
</tr>
<tr>
<td>3. Colorectal with MSI-high pathologic-associated features (Crohn-like lymphocytic reaction, mucinous/signet cell differentiation, or medullary growth pattern) diagnosed in an individual younger than 60 years old.</td>
</tr>
<tr>
<td>4. Patient with colorectal cancer and colorectal cancer or LS-associated tumour diagnosed in at least 1 first-degree relative younger than 50 years old.</td>
</tr>
<tr>
<td>5. Patient with colorectal cancer and colorectal cancer or LS-associated tumour at any age in two first-degree or second-degree relatives.</td>
</tr>
</tbody>
</table>

#LS-associated tumours include tumour of the colorectum, endometrium, stomach, ovary, pancreas, ureter, renal pelvis, biliary tract, brain, small bowel, sebaceous glands, and keratoacanthomas.


Computational models such as *MMRpredict*, *MMRpro* and *PREMM* are available online and perform better than the Revised Bethesda Criteria (Giardiello et al. 2014).

PART B: Literature review
5.2 Immunohistochemistry

Immunohistochemistry (IHC) testing is a preliminary test performed on tumour tissue and assists in identifying the MMR gene (MLH1, MSH2, MSH6 or PSM2) that is most likely to have a mutation (Giardiello et al. 2014; Snowsill et al. 2014; Hedge et al. 2013). IHC, thus, has the added advantage of directing germline testing to a specific gene. Patients with a negative stain would suggest high risk for LS and the individual may, therefore, be recommended for DNA analysis of the relevant gene. There is a lack of good quality evidence for estimating IHC sensitivity and specificity. The EGAPP reported, based on moderate evidence, sensitivity of approximately 83% irrespective of MMR gene involved, and specificity of 88.8% (with wide variations) (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al. 2014; Hedge et al. 2013). The Health Technology Assessment (HTA) conducted by the National Institute for Health Research reported IHC sensitivity that ranged from 73% - 100% and specificity that ranged from 12.5% - 100% (Snowsill et al. 2014). As IHC is performed on tumour tissue, not all patients will be able to undergo IHC.

5.3 Microsatellite Instability

Microsatellite Instability (MSI) testing is a preliminary test performed on the tumour tissue to identify suitable candidates for germline testing (Snowsill et al. 2014). Patients with a high instability would proceed to immunohistochemistry or genetic testing as 10 – 15% of patients with a high instability have sporadic colorectal cancer. Sensitivity and specificity may vary depending on the number of mononucleic markers included, test methodology and protocol for sample preparation. The HTA conducted by the National Institute for Health Research (2014) reported an MSI sensitivity range from 88% to 100%, but a lower specificity range from 68% to 84% (Snowsill et al. 2014). The EGAPP reported, based on
moderate evidence, sensitivities of approximately 89% (for *MLH1* & *MSH2*) and about 77% for *MSH6* (Palomaki et al. 2009). About 5% of MSI have normal IHC results and therefore, it was suggested that both IHC and MSI be performed or to proceed directly to gene testing (Hampel 2009; Hedge et al. 2013). MSI testing is labour intensive, expensive and requires a skilled geneticist (Coetzee et al. 2013).

### 5.4 *BRAF V600E*

Most colorectal cancers with *BRAF V600E* mutations are associated with MSI positive results (Giardiello et al. 2014; Snowsill et al. 2014; Hedge et al. 2013). Almost always, an MMR mutation is not present when *BRAF V600E* mutation is found. Performing *BRAF V600E* testing on tumours with absent *MLH1* staining would identify patients that would not benefit from *MLH1* sequencing. Literature suggested that significant cost savings could be implicated as *BRAF V600E* testing is relatively inexpensive compared to *MLH1* sequencing and *MLH1* is the most common MMR gene associated with absent IHC staining. Sensitivity and specificity of *BRAF V600E* testing is estimated as 69% and 100%, respectively, based on moderate evidence (Giardiello et al. 2014; Snowsill et al. 2014; Hedge et al. 2013).
5.5 Genetic testing

Advantages of genetic testing include:

- confirmation of diagnosis in a proband / family,
- confirmation of the diagnosis in an at-risk family member when the mutation is known and,
- appropriate management can be offered for LS diagnosed individuals and those who tested negative for LS (Giardiello et al. 2014).

Genetic testing in LS is complex as (i) there are a number of cancers to consider in the differential diagnosis, (ii) there is considerable overlap in phenotype and (iii) the testing involves a combination of germline tests and tumour tests (Hampel 2009). It is anticipated that Next-Generation Sequencing (NGS) will allow for simplification of this process as it will provide for the sequencing of all genes involved in LS-associated colorectal cancer in a panel; and at possibly a more reduced cost. (Hedge et al. 2013). Testing strategies are illustrated in Figs 1, 2, 3 and 4 (Giardiello et al. 2014). Studies have shown that up to 25% of LS patients would be missed with the most generous clinical criteria and thus, EGAPP proposed universal testing for persons with colorectal cancer. Although this strategy was supported by the National Comprehensive Cancer Network and other groups, implementation is challenging, especially in resource constrained environments. In these circumstances, traditional testing has been a preferred option (Giardiello et al. 2009).
5.5.1 Universal testing

Universal testing (Fig 1), as proposed by EGAPP, involves testing of all persons with colorectal cancer ≤70 years, and >70 years with a family history suggesting risk for LS (GRADE moderate quality evidence) (Giardiello et al. 2014).

Fig. 1: Universal screening

5.5.2 Traditional testing

Traditional testing involves selective genetic testing based on:
- tumour displaying MMR deficiency; or
- Revised Bethesda Criteria; or
- Amsterdam Criteria; or
- Uterine / endometrial cancer at <50 years; or
- known mutation in family;
- or / and personal risk ≥25% on prediction models.

If the mutation is known (Fig. 2), a negative genetic test result for the mutation on the pedigree would indicate that the pedigree does not have LS (GRADE moderate quality evidence) (Giardiello et al. 2014).

Fig. 2: Traditional testing strategy in the case of a known family mutation


In the case of an affected person (i.e. has cancer) where the mutation is unknown (Fig. 3), IHC and / or MSI would be recommended. If these results do not suggest an MMR mutation, LS is excluded and no further testing is recommended. Conversely, if results are positive, genetic testing would be recommended (Giardiello et al. 2014).

In the case of an at-risk person (person with no cancer) where the family mutation is known, the at-risk person and relevant family members can be diagnosed for LS by genetic testing. Where the family mutation for the at-risk patient is unknown, it is suggested that an affected member be found and, if possible, evaluation of the tumour is suggested, which will direct genetic testing. If an affected member is not found, genetic testing can be performed as per Fig. 4.
Guidelines further recommended that genetic testing should not be offered to at-risk relatives until the mutation had been identified (Vasen et al. 2013; Giardiello et al. 2014). At-risk relatives can then undergo single mutation testing (predictive testing) for the identified gene which is less expensive and reliable. Relatives that have the mutation(s) and defer genetic testing should be treated the same as patients with Lynch Syndrome, whereas relatives that tested negative would follow screening frequency as per the general population. Literature suggested that for every proband, an average of 3 relatives could be tested for LS at a much lesser cost than the cost of testing a proband – thus, reflecting the benefit of identifying a proband (Vasen et al. 2013). Positivity rates of relatives of 39% to 50% were reported for studies conducted in high income countries (Grosse et al. 2015). This means that for every two relatives tested, up to one may test positive.
5.5.3 Genetic testing procedures

Various strategies have been applied to perform genetic testing for LS and to date there are no clear guidelines on best practice (Hampel 2010; Snowsill et al 2014). Practices can become fairly complex and may involve some or all of the following preliminary tests; IHC, MSI, or *BRAF V600E*. Genetic testing involves DNA extraction, polymerase chain reaction (PCR), restriction enzyme digest, Multiplex Ligation-dependent Probe Amplification (MLPA) and / or Sanger sequencing (Hampel 2010).

- PCR amplifies the fragment of DNA carrying the site of the mutation (Hedge et al. 2014);
- Restriction enzyme digest specifically recognize the mutated DNA sequence and cut it. The cut (mutation positive) and uncut (mutation negative) fragments are distinguishable on an agarose gel run in an electric field.
- Sanger sequencing produces a graphic read out showing the exact site of the mutation.
- Multiplex Ligation-dependent Probe Amplification (MLPA) detects deletions/insertions of whole exons of the respective gene(s) (Hedge et al. 2014).

Snowsill et al (2014) reviewed the performance of genetic tests and resolved that Sequencing with MLPA was recognised as the gold standard for diagnosing LS.

Standard operating procedures for genetic testing (Division of Human Genetics, 2015) informed on the actual procedures followed to perform the specific genetic tests for this study. However, the guidelines in terms of which tests to perform was not finalised (GSH Gastroenterology Department and UCT Division of Human Genetics, in progress). Therefore, actual procedures, based on the draft protocols and observation at the time of the study, was recorded for this study.
6. Genetic counselling & patient support

Genetic counselling, by a trained health professional, includes pre-test, post-test and follow-up counselling with every colonoscopy screening session (Giardiello et al. 2014). Appropriate standards and certifications are required as genetic counsellors have to be competent in order to deal with psychological, clinical, ethical and financial issues. Counselling involves informing patients, obtaining informed consent, constructing pedigree trees and disclosure of test results (Giardiello et al. 2014). The most cost-effective approach, under limited funding, is to improve diagnosis in relatives of persons that have already been screened (Vasen et al. 2013; Grosse 2015). Genetic counsellors play a key role in recruiting relatives for testing. Uptake rate of genetic testing in a local study were reported as reasonably high i.e. 97% and 74% for siblings and children, respectively (Bruwer et al. 2012).

7. Screening for colorectal cancer

Colorectal cancer is generally asymptomatic before the cancer has reached a relatively advanced stage (Vasen et al. 2013). The majority of colorectal cancers develop from a polyp, a premalignant form that may exist for years before symptoms of cancer manifest (Lynch et al. 2015). Individuals with LS can benefit from life-saving intensive screening and thus, it is crucial that these individuals be identified via an effective screening programme (Vasen et al. 2013).

Faecal occult blood tests (FOBTs) detect mainly asymptomatic cancers by detecting blood from bleeding cancers (Coetzee et al. 2013). Sensitivity of a single FOBT is about 30% as cancers only bleed intermittently. Although cheap and non-invasive, the low sensitivity of
FOBT is not ideal for screening for LS. Flexible sigmoidoscopy is less technically demanding and less invasive than colonoscopy and does not require full bowel preparation. This procedure allows for visualisation, removal of polyps and tissue biopsy of the left colon. However, about two thirds of Lynch Syndrome-associated colorectal cancers appear proximal to the left colon and may be missed (Lynch 2015; Coetzee et al 2013).

Colonoscopy allows for inspection of the entire colon and, if performed by a skilled professional, provides a sensitivity of up to 100% for detecting cancers and advanced adenomas (Coetzee et al 2013). Two main advantages of appropriate screening are the early detection of cancer and consequently enhances prospects of curative treatment and secondly, the early detection of pre-cancerous lesions which allows for removal of the polyps before it can advance to cancer. There are no randomised controlled studies on routine colonoscopy screening. However, Level IIb evidence (well-designed quasi experimental study) exists that indicated a reduced incidence of colorectal cancer by 62% and 65% - 70% decrease in mortality (Jarvinen et al. 2009; Vasen et al. 2013). In a South African cohort from the same community as this study, Stupart et al (2008) showed that 27% of patients in a no-colonoscopy screening group developed colorectal cancer as opposed to 11% in the group that received colonoscopy screening. In the same study, death from colorectal cancer occurred in 12% of the group that did not undergo colonoscopy screening compared to only 2% in the colonoscopy screening group (Stupart et al. 2008).

Colonoscopy is more invasive, requires sedation and bowel preparation, and has morbidity associated with this procedure (Coetzee et al 2013; Snowsill et al 2014). The most common, serious adverse events related to colonoscopy in the general population are death 0.08/1000, perforation (3.3/1000) and bleeding (11.1/1000) (Palomaki et al 2009). Compliance with colonoscopy is, therefore, lower compared with other procedures.
Adherence to colonoscopy ranged from 60% to 88% in studies conducted in high income countries (Gross 2015). Stupart et al (2008) reported an uptake of 72% in the South African cohort. A very low adherence rate to colonoscopy of 25% was reported in another South African study conducted on LS-positive persons over a 5-year period (Bruwer et al. 2013). Uptake of colonoscopy depends on access to services, acceptance of services, awareness and availability of resources.

Relatives without the mutation(s) should follow cancer screening guidelines as for the general population i.e. every ten years from the age of 50 years. (Giardiello et al. 2014; Snowsill et al. 2014). For LS individuals, most guidelines recommend that biennial colonoscopy should commence at the age of 20 - 25 years or two to five years before the age of the youngest person diagnosed with colorectal cancer in the family. Furthermore, biennial colonoscopy is recommended up to 29 years and annual colonoscopy for persons from 30 to about 60 years or when the risks of colonoscopy outweigh its benefit. It has also been recommended that, due to the reduced penetrance, individuals with MSH6 or PMS2 may commence colonoscopy screening as late as 30 years and 35 years, respectively (Giardiello et al. 2014; Snowsill et al. 2014).

Public sector colonoscopy services in South Africa cater for approximately 80% of the country’s population and are few and limited to secondary and tertiary level care. Furthermore, these colonoscopies are only performed by medical or surgical gastroenterologists. Although there is evidence that simple endoscopy procedures could be provided by non-physicians safely and effectively, there is a paucity of data on non-physicians providing colonoscopy (Day et al. 2014; Ruco et al. 2016). Due to the limited professional skills and services available, colonoscopies are generally not for screening purposes, but are performed on patients that present with symptoms in order to exclude cancer (Personal communication: Thomson, S: Gastroenterology clinic: GSH. 2015).

PART B: Literature review
8. Cost analysis

Genetic-based interventions are complex interventions that can guide clinical decision-making in terms of accurate diagnosis, more focused treatment, potentially limit or prevent disease, prevent hazardous or unnecessary treatments, prolong life and overall promote health (Grosse et al. 2008; Buchanan et al. 2013). Furthermore, genetic information can guide patients and family members in terms of decision-making regarding their own health. In most cases, genetic testing provides information for decision-making, but may not have any direct impact on mortality or morbidity. Screening, similarly, provides information for further action (e.g. polypectomy, curative treatments, etc.). For both genetic testing and colonoscopy, benefits are received later in time. Both these technologies will impact significantly on the consumption of resources. It is imperative, therefore, for decision-makers to assess the benefits and costs of genetic and screening technology; and be able to compare these benefits and costs to various other options (Grosse et al. 2008; Buchanan et al. 2013). Economic evaluations are systematic analysis of relevant healthcare alternatives in order to compare both costs and consequences of alternative options with the intention of informing on a preferred course of action (Drummond et al. 2005). Economic evaluations commonly encountered in healthcare include cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis (CBA). A CEA compares cost and consequences (effectiveness) of different alternatives and generally, only one outcome is considered per cost incurred. Outcomes for CEA are measured in natural units (e.g. blood pressure – mmHg). A CUA compares costs and consequences in terms of patient utility (e.g. quality adjusted life year – QUALY) and more than one outcome may be considered for the patient (Drummond et al. 2005). The limitation of performing a CUA for genetic testing is that, generally, QUALYs (utilities) are calculated directly for the affected individual. The extended effect (benefit or harm) to
family members in terms of knowledge for informed decision-making are often excluded and would require specific modelling in order to be considered. Cost-benefit analysis (CBA) considers costs and a broad range of different patient outcomes. In a CBA both costs and outcomes are valued in monetary terms (Drummond et al. 2005). CBAs take into consideration both health and non-health outcomes, and may not be useful if a decision-maker only wants to focus on optimising health outcomes (Grosse et al. 2008).

Partial economic analysis allow for important intermediate stages of understanding the costs and consequences of alternative healthcare programmes (Drummond et al. 2005; Gray et al. 2012). In this study, a partial economic evaluation will be performed that focuses on costs i.e. collecting primary data to determine the cost of providing colonoscopy and germline tests for patients with Lynch Syndrome and their relatives. The reason for collecting primary cost data is that even with attempts to standardise costing methodologies, availability of financial data and financial practices impact on results and therefore, data is very much time, context and country specific. Furthermore, estimating costs from medical charges may not produce accurate results as charges may be influenced by factors such as service provider monopolies, cross-subsidisations, profit generation or negotiated contracts (Drummond et al. 2005; Gray et al. 2012).

Table 2 reflects the costs reported in various cost-effectiveness studies performed in different countries (Gross 2015). Total screening costs were around $2 242 to $3 345. One study was unusually high at a total cost of $6 312. Generally, the largest contributors towards the screening costs were the genetic testing for MLH1 and colonoscopy. Long-term the colonoscopy cost will be the main cost driver as the other costs are once-off costs. The lowest cost contributors were the genetic counselling costs and approaching relatives. The predictive tests for relatives were in all cases significantly lower than the genetic sequencing for MLH1 (identifying the mutation). This indicates the value of identifying a
family mutation – i.e. relatives may be identified at a much lower cost and may benefit more from colonoscopy screening as they may not have cancer yet as opposed to the proband who often present with cancer already.

Table 2: Base case estimates of costs of routine testing and colonoscopy for Lynch Syndrome in patients with colorectal cancer and first degree relatives, in 2014 US $

<table>
<thead>
<tr>
<th>Study</th>
<th>Pre-test counselling</th>
<th>Post-test counselling</th>
<th>Counselling for gene sequencing</th>
<th>IHC</th>
<th>Gene sequencing for MLH1 gene</th>
<th>Approaching relatives</th>
<th>Test for relative (predictive)</th>
<th>Combined test and counselling cost for relatives</th>
<th>Colonoscopy unit cost</th>
<th>TOTAL COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mvundura et al. (2010) USA</td>
<td>22</td>
<td>106</td>
<td>194</td>
<td>290</td>
<td>899</td>
<td>350</td>
<td>61</td>
<td>441</td>
<td>1043</td>
<td>3345</td>
</tr>
<tr>
<td>% of total cost</td>
<td>0.66</td>
<td>3.17</td>
<td>5.80</td>
<td>8.67</td>
<td>26.88</td>
<td>10.46</td>
<td>1.82</td>
<td>13.18</td>
<td>31.18</td>
<td>100</td>
</tr>
<tr>
<td>Ladabaum et al. (2011) USA</td>
<td>NR</td>
<td>112</td>
<td>198</td>
<td>300</td>
<td>942</td>
<td>118</td>
<td>492</td>
<td>610</td>
<td>690</td>
<td>2970</td>
</tr>
<tr>
<td>% of total cost</td>
<td>NR</td>
<td>3.77</td>
<td>6.67</td>
<td>10.10</td>
<td>31.72</td>
<td>3.97</td>
<td>16.57</td>
<td>20.54</td>
<td>23.23</td>
<td>100</td>
</tr>
<tr>
<td>% of total cost</td>
<td>1.12</td>
<td>6.07</td>
<td>0.2</td>
<td>8.21</td>
<td>52.81</td>
<td>3.43</td>
<td>15.74</td>
<td>19.18</td>
<td>9.19</td>
<td>100</td>
</tr>
<tr>
<td>Snowsill et al (2014; 2015) UK</td>
<td>0</td>
<td>0</td>
<td>103</td>
<td>366</td>
<td>714</td>
<td>103</td>
<td>265</td>
<td>368</td>
<td>911</td>
<td>2565</td>
</tr>
<tr>
<td>% of total cost</td>
<td>0</td>
<td>0</td>
<td>4.02</td>
<td>14.27</td>
<td>27.84</td>
<td>4.02</td>
<td>10.33</td>
<td>14.35</td>
<td>35.52</td>
<td>100</td>
</tr>
<tr>
<td>Severin et al (2014) Germany</td>
<td>57</td>
<td>161</td>
<td>0</td>
<td>166</td>
<td>52688</td>
<td>57</td>
<td>281</td>
<td>338</td>
<td>265</td>
<td>6312</td>
</tr>
<tr>
<td>% of total cost</td>
<td>0.90</td>
<td>2.55</td>
<td>0.2</td>
<td>2.63</td>
<td>83.46</td>
<td>0.90</td>
<td>4.45</td>
<td>5.35</td>
<td>4.20</td>
<td>100</td>
</tr>
<tr>
<td>Barzi et al (2015) USA</td>
<td>NR</td>
<td>112</td>
<td>198</td>
<td>300</td>
<td>942</td>
<td>118</td>
<td>492</td>
<td>610</td>
<td>690</td>
<td>2970</td>
</tr>
<tr>
<td>% of total cost</td>
<td>NR</td>
<td>3.77</td>
<td>6.67</td>
<td>10.10</td>
<td>31.72</td>
<td>3.97</td>
<td>16.57</td>
<td>20.54</td>
<td>23.23</td>
<td>100</td>
</tr>
</tbody>
</table>

NR: Not reported  * Not added to total (included in combined counselling and test)
# Genetic testing costs is not higher in Germany. The German reimbursement for gene sequencing is an outlier.


The perspective and target audience assumed in an economic analysis are significant as these inform on the costs and other considerations that will be included in the analysis (Drummond et al. 2005; Grosse et al. 2008). Most economic analyses are performed from the provider perspective; however a more societal approach may be more appropriate for genomics due to its indirect impacts (Buchanan et al 2013). Furthermore, health practitioners place significant value on informed decision-making by the patient, whereas
for health care payers this may not be relevant (Buchanan et al. 2013). For this study, however, a health provider perspective will be applied as the aim of the study is to estimate and compare the cost of colonoscopy screening as a step towards assessing affordability. In this case, the key target audiences will be the service providers, policy makers, government and researchers.

Costs may be determined by stochastic analysis i.e. understanding that the resources required may vary from patient to patient due to known and unknown variables, and therefore cannot be predicted accurately (Gray et al. 2012). In this case, in practice, the variations between patients may be considerable. In a deterministic analysis, a model treatment is assumed per patient and costed. (Gray et al. 2012). Germline testing for identifying the responsible MMR gene mutation may have significant variation in cost between patients as the number of tests required to identify the gene mutation vary from patient to patient (Buchanan et al. 2013). In many cases, genetic testing has a research arm associated with it which impacts on testing procedures applied. For LS, national standard protocols for genetic testing are not established and practices may vary from laboratory to laboratory. The timing of collecting costs is also important as standard practices for genomic interventions evolves over time and different techniques have different sensitivities and specificities (Buchanan et al. 2013). To overcome these challenges, and as recommended by Grosse et al. (2008) costs should, therefore, be based on actual utilization data and processes followed at GSH and UCT. Additionally, analysis of data should be restricted to a specific period to ensure that the latest technologies used at GSH / UCT were considered only.

Three stages are generally involved in performing a cost analysis i.e. (i) identifying resources required, (ii) measuring / quantifying these resources using physical units and

PART B: Literature review
(iii) valuing these resources (Drummond et al. 2005; Gray et al. 2012; Mangham 2009). Two approaches are commonly used for identifying resources; namely, gross-costing (referred to as top-down costing) and micro-costing (referred to as bottom-up costing) (Drummond et al. 2005; Gray et al. 2012). Gross-costing identifies costs in bundles e.g. cost of a day in hospital, whereas micro-costing involves identifying and costing all activities, consumables, staff, etc. related to the day in hospital. The approach used will depend on the ease of collecting the data and the resources-use difference between the comparisons (Gray et al. 2012). Since very little costing data and bundle costs estimates are available on colonoscopy and germline testing in the public sector, a predominantly micro-costing approach is more appropriate. Measurement of resource quantities may be collected by observation, patient or staff interviews, completing questionnaires or folder reviews. Valuing of resources should, ideally, reflect opportunity costs. In practice, market prices are assumed to be a reasonable approximation of opportunity costs (Drummond et al. 2005; Gray et al. 2012). Market prices, however, have an element of profit attached to it ((Drummond et al. 2005; Gray et al. 2012) and in the public sector in South Africa, prices may differ significantly between private and public sector. In South Africa, the Uniform Patient Fees Schedule (UPFS) is used as a reference price list in the public sector to reflect State prices (Department of Health: Western Cape 2015). These prices for services are often approximations and not always based on actual costs (Personal communication: Kathrie-Salie, M: Directorate Finance: Department of Health - Western Cape). Thus, in our study, resources for services will be valued by collecting primary data rather than using reference lists, hospital charges or market prices.

Costs are estimated in terms of capital costs and recurrent costs (Drummond et al. 2005; Gray et al. 2012). Capital costs are investments made at a single point in time and represent an investment in assets used over a period of time. The cost of a capital item is
associated with the lost opportunity of investing the capital expenditure for an alternative benefit. Most capital costs depreciate over time, while some, such as land and buildings maintains its value and are non-depreciable. The “equivalent annual cost” is determined by annuitizing the initial capital expenditure. Annuitizing takes into account opportunity cost, depreciation and the life-years of the capital item. Recommended discounting rates for annuitizing is 3%. Life-years of a capital item or equipment reflect the number of usable years of the item (Drummond et al. 2005; Gray et al. 2012). – Buildings are usually allocated usable life-years of 30 to 50 years, equipment five to ten years, and furniture one to five years (Drummond et al. 2005; Gray et al. 2012; Mangham 2009; Somda 2007).

Shared costs (e.g. overhead costs) may be allocated in a variety of ways, but are usually allocated based on the different activities that drive the departments e.g. paid hours for staff, square metres for housekeeping, etc. (Drummond et al. 2005; Gray et al. 2012). The unit used to determine the allocation of shared costs must be as homogenous as possible with regards to cost across services and must be associated with every patient concerned (Drummond et al. 2005; Gray et al. 2012).

Total costs provide policy makers and service providers with information of total expenditure, budget requirements and affordability (Drummond et al. 2005; Gray et al. 2012). Average unit cost data provide information, on average, of cost changes when data is generalised across different settings or patient utilisation patterns. Average unit cost may differ as it may include settings of different levels of production efficiency. Marginal costs provide information on the additional cost for every additional unit produced. This is important for scaling up of services (Drummond et al. 2005; Gray et al. 2012). In our study, average unit costs for colonoscopy and genetic testing will be estimated and this
Programmes with differential timing of resource outlays need to accommodate for time preferences. Most people desire a positive time preference because of (i) opportunity costs, (ii) the value of an amount of money today is worth more than the value of the same amount of money in the future, and (iii) uncertainty of the future. The discount rate is based on a value judgement by society and reflects the extent to which society is willing to postpone their gratification for the benefit of the future generations. Future costs are, thus, discounted to present value. There is not yet consensus on the discount rate to use in economic evaluations. However, discount rates are published in many countries. Discount rates commonly reflected in literature is usually used in countries where discount rates are not published. As the discount rate is a subjective variable, sensitivity analysis on no discount rate and commonly published discount rates such as 3% or 5% are recommended. (Drummond et al, 2005; Department of Health: Government Gazette No. 36118).

Sensitivity analysis is a method that is used to deal with uncertainty (Drummond et al. 2005). Sensitivity analyses are based on uncertainties (parameters) reflected in literature or in our study; and inform on the extent to which these parameters will influence costs or outcomes (Drummond et al. 2005). According to literature, discount rates, adherence to colonoscopy and positivity rate of relatives are main parameters that influence colorectal screening costs in LS (Gross 2015).

A number of cost-effectiveness studies on LS screening has been published (Snowsill et al. 2014; Grosse 2015). However, these studies focused on high income countries and generalisability to the South African context poses a challenge.

A Health Technology Assessment (HTA) published in 2014 included a systematic review of 32 cost-effectiveness studies (Snowsill et al. 2014). Most of the studies were conducted in the United States of America and were designed from a health service provider perspective. The most frequently used test strategy could not be determined from the review as the studies employed different tests and combinations of tests. Furthermore, different studies made different assumptions and this complicated direct comparability of studies. The management strategies across the studies were fairly consistent and included biennial to annual colonoscopy screening from the age of 25 years, with extensive colorectal surgery on diagnosis of colorectal cancer. Many of the studies failed to comply with the Drummond checklist (Drummond et al. 2005). The review could not inform on the consistency with regards to the strategies or individual test that would be most cost-effective. All studies, however, concluded that screening for LS compared to no screening was cost-effective (Snowsill et al. 2014). Similar findings were found in a review by Grosse (2015) who also concluded that cost-effectiveness is subject to the alternative strategies available and the methods of collecting and valuing costs. He further suggested that in order to inform appropriately on cost-effectiveness for screening for LS, unlike most of these studies where a number of assumptions are applied, actual real-life clinical practice should be documented as costs, adherence to colonoscopy, number of relatives tested vary across populations (Gross 2008).
Snowsill et al. (2014) further conducted a health technology assessment comparing eight screening strategies. The more tests that were performed in sequence, the greater the costs as well as the specificity. Little, however, is reported in the literature regarding sensitivity and specificity when performing tests sequentially except for *BRAF V600E* test after IHC or MSI with *MLH1*. The HTA found that, compared to no testing as the base case, MSI + *BRAF V600E* + genetic testing produced the lowest ICER. Sensitivity analysis indicated that, even at low rates of acceptance of diagnostic tests and genetic counselling, LS testing was found to be cost-effective compared to no testing. Sensitivity analysis performed on widely varying the number of relatives per proband, including no relatives, found screening for LS more cost-effective than no screening. LS diagnosis and true LS status greatly influenced life expectancy. The total number of colonoscopies was influenced by the correct diagnosis of LS and adherence to screening. Strategies that increase the number of false positives and reduce the number of false negatives resulted in an increased number of colonoscopies and therefore increased costs. Strategies that identified more LS positive patients reduced the expected number of colorectal cancers for probands and relatives. This is due to the impact of colonoscopy screening as a preventative measure for colorectal cancer. Universal gene testing, therefore, resulted in the lowest number of colorectal cancer in both probands and relatives, but was the most expensive. Clinical outcomes were also strongly influenced by compliance with preventative measures. Higher number of colonoscopies produced less colorectal cancer and higher life expectancies. The majority of the diagnosing cost for the cohort was due to diagnosing the probands, as opposed to diagnosing the relatives. Costs were driven by the number of tests taken. Compared to long-term costs, diagnostic costs were small and did not influence the variation in costs between strategies. The most influential cost driver, long-term, was the cost of colonoscopies. During univariate sensitivity analysis, ICERS were nearly doubled or
halved when colonoscopy costs were doubled or halved, respectively. As QUALY’s increased, the total costs increased across the strategies as expected due to the preventative measures used. The time of diagnosis, the age at diagnosis, the stage at diagnosis and the site of the cancer, impacts on the management of colorectal cancer and this may vary substantially from patient to patient. It is, thus, an enormous task to estimate the cost of treating cancer and data cannot be easily generalised. However, in the HTA conducted in the United Kingdom, it was found that preventative costs outweighed the increased savings in cost from colorectal cancer treatment (Snowsill et al. 2014).

In summary, the number of colonoscopies was the main cost driver; and this was influenced by number of LS positive probands, adherence rate to colonoscopy and number of positive relatives that tested positive.

10. Summary of literature review

- Individuals with LS have a high risk for colorectal cancer and the onset of cancer occurs at ages when persons are economically active and support families. South African families with LS have been implicated with the MMR genes, \textit{MLH1} and \textit{MSH2}, which presents the highest risks (40\% to 70\%) for colorectal cancer.
- The literature showed a paucity of randomised control trials on the benefit of colonoscopy in colorectal cancer. However, observational studies provided acceptable evidence that colonoscopy screening is the only effective screening strategy for colorectal cancer in LS and reduced mortality and the incidence of colorectal cancer.
- Differential diagnosis of LS (family history, histology, computational model, etc.) lacks sensitivity and specificity to adequately identify LS individuals for colonoscopy screening. Genetic testing provides a definitive diagnosis for LS.

- Standard protocols for genetic testing are complex and vary, and best practice guidelines have not been established. Costs of genetic testing may, therefore, differ significantly according to the series of tests performed, performance standards, laboratory protocols, costs of resources, etc. Generalisability of published data to varying settings is, therefore, challenging and often not possible.

- Timing of an economic evaluation is critical as genetic testing technology evolve continuously.

- Generally, genetic testing do not impact directly on health outcomes that are important for a service provider (e.g. mortality or morbidity), but inform on further management of a patient. Thus, it is important to include the costs of the both the genetic testing and the intervention (e.g. colonoscopy) in an economic analysis.

- Cascade genetic testing i.e. testing of a relative is less costly than diagnosing a proband; and the benefit for the relative may be greater as he / she may not have cancer yet. Thus, cascade testing reflects the benefit of genetic testing and has to be considered when assessing costs and benefits.

- Long-term, colonoscopies contribute to the majority of the costs of screening for colorectal cancer. Parameters that influence the number of colonoscopies in the screening process include discount rates, adherence to colonoscopy and positivity rate of relatives.

- No published local study involved the economic aspects related to providing a colonoscopy screening service for Lynch Syndrome.
11. Conclusion

An overview of the literature indicated that publications focused predominantly on high income countries which are not generalisable to South Africa. A number of evidence-based guidelines and one detailed health technology assessment provided best practice evidence as well as cost-effectiveness data. Though these publications provided guidance on recommended practices, practices in South Africa differ due to availability of resources, skills and equipment. Grosse et al. (2008) recommended that in order to inform appropriately on cost-effectiveness for screening for LS, unlike most of these studies where a number of assumptions are applied, actual real-life clinical practice should be documented. The aim of our study, therefore, is to estimate from actual expenditure and utilisation data, the costs of implementing screening options for colorectal cancer for patients with LS.
References


Department of Public Service and Administration SA. 2015. Cost of living adjustment (COLA) 2015. Pretoria: Department of Public Service and Administration SA.


PART B: Literature review

Finance Department: Groote Schuur Hospital, 2015. Basic Accounting System (BAS) report. Groote Schuur Hospital


PART B: Literature review


PART B: Literature review


Somda, Z.C., Meltzer, M.I., Perry, H.N. 2007. SurvCost 1.0: a manual to assist country and district public health officials in estimating the cost of the implementation of IDSRS. CDCP. Department of Health and Human Services. USA.


PART C: JOURNAL ARTICLE

Full title:

A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a tertiary hospital, South Africa

Short title:

Cost analysis of colorectal cancer screening in Lynch Syndrome, South Africa
Abstract

Aim: Individuals with Lynch Syndrome have a 25% to 75% lifetime risk of colorectal cancer and the cancer generally presents at an early age. It is, thus, important to establish the cost of strategies to prevent or delay the onset of cancer. Colonoscopy was the only screening method shown to be effective. This study compared the cost of two screening approaches - colonoscopy only (Strategy 1) versus genetic testing for Lynch Syndrome followed by colonoscopy for the individuals that tested positive (Strategy 2).

Method: A comparative cost analysis of two screening approaches was conducted from the health service perspective at a tertiary hospital. Probands that were selected for genetic testing between 01 November 2014 and 30 October 2015, and their relatives were analysed. From this cohort, all probands and their 1st degree relatives were analysed according to Strategy 1. From the same cohort, probands that tested positive for a mutation and their 1st degree relatives were analysed according to Strategy 2. Total costs for the two screening strategies were estimated and compared. Sensitivity analyses were performed on adherence rates to colonoscopy, positivity rates of relatives and discount rates.

Results: A total of 40 families were studied. The total cost for Strategy 1 amounted to R4 932 718 ($332 617) compared to R390 308 ($26 319) for Strategy 2 (Discount rate 3%; Adherence 75% and Positivity rate of relatives 45%). Base case analysis indicated a difference of 90% less in the total cost for Strategy 2 compared to Strategy 1. One-way sensitivity analyses showed that the difference in cost between the two strategies was not sensitive to changes in discount rates, adherence rates or positivity rates of relatives.

Conclusion: Colonoscopy screening for Lynch Syndrome and at-risk patients was substantially less costly when combined with genetic testing. Effectiveness of the screening programmes should be established through further research.

Key words: genetic testing, Lynch Syndrome, HNPCC, colorectal cancer, colonoscopy, cost-effectiveness
1. Introduction

In South Africa, colorectal cancer is the fifth most common cancer, with approximately 4,697 new cases and 3,138 deaths reported in 2012 (National Health Laboratory Services: Globocan, 2015). Just over half of the new cases diagnosed and 41% of deaths occurred in individuals younger than 65 years of age (National Health Laboratory Services: Globocan, 2015). The most common cause of hereditary colorectal cancer is Lynch Syndrome (LS) which accounts for approximately 3% to 5% of all colorectal cancers (Graham et al. 2012; Bonadona et al. 2011; Snowsill et al. 2014).

LS is clinically defined as a disorder that predisposes individuals to colorectal cancer, endometrial cancer and certain other cancers as a result of an underlying germline mismatch repair (MMR) gene mutation (Vasen et al. 2013). The disorder presents with high rates of multiple primary tumours, has an early age of onset and generally has an absence of typical risk factors (Vasen et al. 2013). Carriers of a mutation in any of the MMR genes have a lifetime risk for colorectal cancer of 25% to 75%, compared to a 5% lifetime risk in the general population (Cohen et al 2014; Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al. 2013). The highest risks, in the region of 40% to 70%, are associated with individuals with MLH1 and MSH2 mutations, with lower risks reported for MSH6 (10% - 22%) and PMS2 (15% - 22%) (Bonadona et al. 2011; Steinke et al. 2013; Vasen et al. 2013; Giardiello et al. 2014). LS-associated mutations have an autosomal dominant pattern i.e. if a parent carries the mutation then there is a 50% chance that the mutation will be passed on to the child (Snowsill et al. 2014).

Colorectal cancer is the most common cancer associated with LS (Snowsill et al. 2014; Vasen et al. 2013). Progression of adenoma to carcinoma is approximately five times more accelerated in individuals with LS compared to sporadic and familial colorectal cancers. Furthermore, colorectal cancer is generally asymptomatic until it has reached an advanced
stage (Snowsill et al. 2014; Vasen et al. 2013). As colorectal cancer has a relatively earlier onset in LS individuals than occurs in sporadic forms (Bonadona et al. 2011; Cohen, et al. 2014; Snowsill 2014), persons affected are usually economically active and support families. Thus, preventing or delaying cancer onset, would have social as well as economic benefits. An effective screening programme is fundamental for early detection and successful management of colorectal cancer (Snowsill et al. 2014; Vasen et al. 2013). Advantages of appropriate screening are the early detection of cancer and consequently improved chances of curative treatment; and the early detection of pre-cancerous lesions which allows for removal of the polyps before they can progress to cancer (EGAPP 2009; Giardello et al 2014). Colonoscopy is the only screening method that has proved to be effective for these individuals (Snowsill et al. 2014; Vasen et al. 2013). Studies conducted in high income countries have shown that effective colonoscopy screening programmes reduced mortality by 62% to 72% (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014). Stupart et al. (2009) showed an 80% decrease in mortality in a South African study, based on the communities which are the subjects of the present study. For the general population colonoscopy screening every five to ten years is recommended for individuals commencing from around 50 years old (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014). However, for LS-affected and at risk individuals biennial colonoscopy is recommended for persons from as young as 25 years old and annual colonoscopy is recommended for persons from 30 years to around 70 years old (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014).

In a resource-constrained environment, accurate prediction of individuals at high risk of colorectal cancer who will benefit from colonoscopy is intuitively desirable. Effective prediction will leave those at low risk of disease unexposed to the hazards of potentially invasive screening procedures, as well as optimise the use of scarce resources such as
equipment and skilled staff. Genetic testing to diagnose LS allows for identification of individuals at high risk of colorectal cancer (Snowsill et al. 2014).

The lack of genetic testing for LS and colonoscopy screening programmes in South Africa pose a major drawback for the management of colorectal cancer in individuals with LS. Also, unlike index screening colonoscopy, with genetic testing it is possible to determine if a patient has LS (Giardiello et al. 2014; Snowsill et al. 2014). We, thus, hypothesised that genetic testing with colonoscopy screening will reduce the need for intensive colonoscopy on a large number of patients and consequently, reduce the cost of screening. Furthermore, determining the costs of these services is a key initial step to assessing affordability and successful implementation of such services. Thus far, no published study has assessed the cost implications of colonoscopy and genetic testing screening service for patients with LS in South Africa. Grosse et al. (2008) recommended that in order to inform appropriately on cost-effectiveness for screening for LS, actual real-life clinical practice should be documented. Published studies (Snowsill et al. 2014; Grosse 2015) indicated that long-term, colonoscopy costs were the biggest cost drivers. Preventative measures (colonoscopy) exceeded the cost savings from the delayed management of cancer. In terms of genetic testing, costs for diagnosing a proband exceeded the cost for diagnosing a relative. Adherence to colonoscopy, uptake of genetic testing and positivity rates of relatives are the key parameters that influence total costs of colonoscopy programmes (Snowsill et al. 2014; Grosse 2015).

This study estimated and compared the cost of two screening approaches – intensive colonoscopy only for individuals considered at an increased risk of LS (e.g. probands or their first degree relatives) versus genetic testing for LS of at risk individuals followed by intensive colonoscopy only for the individuals who tested positive.
2. Method

2.1 Study design and objectives

A comparative cost analysis from the health service perspective, using a micro-costing and ingredients-based approach was conducted. Costs were collected in 2015 and presented in the 2016 South African Rands and US Dollars. The unit costs for genetic testing and colonoscopy were estimated; and the total number of colonoscopies required for each strategy was projected. This information was utilised to estimate and compare the total cost for the two strategies.

2.2 Screening strategies

Two screening strategies for colorectal cancer were considered, based on what is currently available at GSH and the research interface with the Human Genetics Research Unit in the Division of Human Genetics at UCT. Both strategies were applied to the same study cohort and costed. Strategy 1 involved intensive colonoscopy screening for all patients with colorectal cancer who were suspected of having LS based on the Revised Bethesda Criteria, as well as their 1st degree relatives. Strategy 2 involved intensive colonoscopy screening only for probands and 1st degree relatives with a genetic test-confirmed diagnosis of LS. Individuals who were negative on germline testing were managed as per the general population i.e. colonoscopy every 10 years from the age of 50 years. Intensive colonoscopy screening involved biennial colonoscopy for patients under 30 years of age, and annual colonoscopy for individuals aged 30-60 years. Individuals older than 60 years were managed as per the general population i.e. colonoscopy every 10 years (Voster, A: Division of Human Genetics: UCT, personal communication 2015).
2.3 Setting and population

The study was undertaken at Groote Schuur hospital, a public sector tertiary hospital in Observatory in Cape Town that provides sub-specialist care. In South Africa, approximately 80% of the population seeks health care in the public sector (Department of Health, 2014). The study included individuals from the Western Cape and Northern Cape provinces. Subjects were recruited from the DNA and pedigree database (Ethics approval: HREC REF: 217/2010) in the Division of Human Genetics at the University of Cape Town (UCT).

In this study, a proband is defined as the first medically identified individual in a family affected with a disorder and serves as the starting position for the genetic study of the family. Probands captured on the database were selected according to the Revised Bethesda Criteria after presenting with colorectal cancer or other LS-associated cancer; and may or may not have LS (Voster, A: Division of Human Genetics: UCT, personal communication 2015). As genetic testing is evolving and becoming more affordable or available, different test strategies have been applied over the years. To ensure that the latest available genetic procedures / tests employed were used to estimate costs, analysis of data was limited to probands tested between 01 November 2014 and 31 October 2015. A total of 40 probands and 934 relatives (40 families) on the DNA database were analysed according to patient demographics and screening strategy 1 and 2 i.e. the two screening options were applied to the same 40 families and costed (For details of the analysis - see Part D: Appendices: S1 and S2 Figs). From the 40 families, only probands and their first degree relatives (FDRs) were identified to receive colonoscopy screening as per the two screening strategies. FDRs are parents, children or siblings of the proband. FDRs of LS positive individuals have a 50% chance of having the LS-mutation (Snowsill et al. 2014) and were thus selected as high risk. Furthermore, individuals <25 years, >60 years,
deceased, spouses and family of spouses were excluded as they would not be eligible for colonoscopy screening. For Strategy 2, individuals were also assessed according to the genetic test results and only LS-positive individuals were assessed in terms costs for Strategy 2. The genetic tests performed and the results thereof are illustrated in Part D: Appendices: S3 Fig. Test results were derived from the National Health Laboratory Services (NHLS) and the DNA database. Surgical procedures performed were obtained from patient medical records. Five patients that had total colectomies were excluded as their screening procedures would not be done by colonoscopy. The number of colonoscopies required per proband and per FDR up to the age of 70 years was projected per screening strategy, taking into account the actual age of the individual.

In summary, for strategy 1, a total of 146 individuals were identified as eligible for colonoscopy. The total number of colonoscopies per lifetime for the eligible individuals for Strategy 1 was estimated as 2 671. For strategy 2, all 40 probands received genetic testing and only LS-positive probands and their families were further analysed for eligibility for colonoscopy. Thus, for strategy 2, a total of 12 individuals were identified as eligible for colonoscopy and a total of 264 colonoscopies were estimated for the lifetime for these individuals.

2.4 Colonoscopy

Colonoscopy is a 30 to 60 minutes procedure performed in a dedicated, equipped room (Algar, U: Surgical Gastroenterology Unit: GSH, personal communication 2015). A colonoscope is inserted into the rectum, through the colon and as far as the caecum. Prior to the procedure, patients are given a special cleansing preparation to clear the bowel. Sedatives may be given for pain control and to relax the patient. An intravenous cannula is prepared in the event that patients may require intravenous fluid or medication. The patient’s heart rhythm and blood pressure is monitored continuously. Post-colonoscopy,
the patient is kept in an observation area for one to two hours (Algar, U: Surgical Gastroenterology Unit: GSH, personal communication 2015).

2.5 Genetic testing procedures

The reflex genetic testing procedure followed by the Division of Human Genetics at UCT for diagnosing LS was applied in this study. A database of all colorectal patients operated on at GSH is maintained and any patient meeting the Revised Bethesda Criteria underwent genetic testing (Voster, A: Division of Human Genetics: UCT, personal communication 2015; Coetzee 2013). Where possible, Immunohistochemistry (IHC) testing was used routinely as a first line preliminary screening test. Negative staining for a specific gene on IHC testing suggested a mutation affecting the respective gene and an increased risk for LS. If the IHC showed presence of all genes, but a strong clinical suspicion existed (e.g. family history, or relatively young age at diagnosis), the patient would be offered Microsatellite Instability (MSI) testing. MSI testing was only provided on request as it is relatively expensive, labour intensive, and requires a skilled geneticist. IHC and MSI were provided by the NHLS. Germline testing was provided by NHLS and the Division of Human Genetics, UCT. Genetic testing encompassed DNA extraction from whole blood following venepuncture, followed by testing for the five common founder mutations, i.e. mutations known to affect large family communities in our environment. The founder mutations were resolved by:

(i) A polymerase chain reaction (PCR), amplifying the fragment of DNA carrying the site of the mutation; followed by a restriction enzyme digest, which will specifically recognise the mutated DNA sequence and cut it. The cut (mutation positive) and uncut (mutation negative) fragments are distinguishable on an agarose gel run in an electric field (Hedge et al 2013), or

(ii) PCR followed by direct Sanger sequencing – which produces a graphic read out showing the exact site of the mutation (Hedge et al 2013), or
(iii) Multiplex Ligation-dependent Probe Amplification (MLPA) which detects deletions/insertions of whole exons of the respective gene(s) (Hedge et al 2013).

Where a previously identified mutation that is not one of the founder mutations was suspected, Sanger sequencing was done and if positive, this was followed by another sequencing test on a separate day, and preferably on DNAs from a separate blood sample, for quality assurance purposes. Only on identification of the MMR gene mutation in the proband, would the at-risk relatives be offered genetic testing for the identified MMR mutation (predictive testing). BRAF V600E was not offered due to its technical complexity. A genetic counsellor provided counselling prior to and after genetic testing, as well as follow-up counselling with every colonoscopy performed. Informed consent was obtained prior to genetic testing (Voster, A: Division of Human Genetics: UCT, personal communication 2015; Coetzee, 2013).

In summary, IHC was performed on probands with suitable colon tissue available for this test (22 individuals). All 40 probands received screening genetic tests i.e. the Common Founder test (39 individuals) or a Sequencing test for those with a known family mutation that was not a founder mutation (one individual). Only probands with LS-positive screening tests (4 individuals) received quality assurance / confirmatory tests i.e. digestive test and / or another sequencing test. See Part D: Appendices: S3 Fig for the flow diagram of tests performed.

2.6 Cost analysis

Capital, overhead and personnel costs were computed in order to estimate the costs for colonoscopy and genetic testing. The costs for performing colonoscopy and genetic testing were identified, quantified (measured) and then valued (Drummond et al 2005; Gray 2012). (See Part D: Appendices: S1 Table to S4 Table for examples of allocation of costs).
The equivalent annual cost of capital items were estimated by annuitizing the initial capital expenditure using a discount rate of 3% (Drummond et al 2005; Glick et al. 2007; Mangham 2009). Annuitizing makes allowance for opportunity cost, depreciation and useful clinical life years of capital items. The following useful life-years were assumed - buildings: 30 years; major equipment: 5 to 10 years; furniture: 10 years; and small equipment: 1 – 5 years (Drummond et al 2005; Somda et al. 2007). For shared building areas, equipment and furniture, the proportion of total utility (e.g. proportion of colonoscopy patients or proportion of total time) was used to estimate costs. For the diagnostic laboratory equipment, an efficiency rate of 65% and 70% was applied. The NDOH/CSIR/DBSA Order of Magnitude Estimator for New Hospitals (Department of Health: National 2014) and architectural drawings (Department of Health: Public Works 2015) were used to obtain costs for building spaces. Construction firms provided costs for a diagnostic laboratory. Equipment costs were obtained from medical suppliers. Furniture items were identified from asset registers (Feb 2016) and the costs were derived from government contracts and suppliers. An 8% mark-up was allocated for maintenance of equipment (Rademeyer: Deputy Director: WCGH Department of Public Works, personal communication 2015. Building and land maintenance costs were included in the Overhead and Maintenance category.

The GSH Finance report (BAS report 2015/16) and the UCT Finance Department provided cost information for shared overheads such as electricity, laboratory costs, housekeeping, stationery, maintenance, etc. Proportions in terms of colonoscopy patients or floor space, as appropriate, were used to allocate shared overhead costs. Costs for managerial and administrative overheads were estimated from the GSH personnel report (PERSAL report 2015) and government salary packages (COLA: Appendix B to DPSA Circular 1 of 2015); and were allocated according to the proportion of GSH staff involved in colonoscopy.
For personnel costs, a unit cost (cost per minute) was determined by dividing the annual total cost to company (CTC) by the annual total working minutes of the staff member. This unit cost was multiplied by the total time utilised by the staff member to perform the required task to obtain staff costs. GSH personnel report (PERSAL report Nov 2015), government salary packages (COLA: Appendix B to DPSA Circular 1 of 2015) UCT staff salaries (UCT Finance Department) were used to value staff costs.

Shared consumables costs were allocated according to the proportion of ward patients who underwent colonoscopy, whereas consumables and pharmaceuticals that were not shared were valued in terms of the quantities used (Department of Health & Treasury Contract Circulars 2012 to 2017).

The average unit cost for colonoscopy was estimated by dividing the total annual costs for colonoscopy by the number of colonoscopies performed per annum.

Costs for genetic tests were obtained from the NHLS and certain genetic tests performed at UCT were calculated using the ingredients approach as noted above. The cost of genetic testing varied amongst patients depending on the type of test and the number of tests conducted on the patient. Thus, the unit costs for genetic testing were estimated by calculating the weighted average cost for genetic testing where the weighting was applied according to the proportion of patients that required a particular test or series of tests.

The estimation of costs was based on the assumptions that:

- individuals undergoing colonoscopy screening have mortality rates as per the general population (Statistics South Africa 2015), as mortality rates for LS individuals in our cohort were not available at the time of the study. This may reflect an overestimation of costs - see section 6: Limitations; and
- all persons selected for genetic testing would be willing to undergo genetic testing.

To compare programmes with differential timing of resource outlays, time preference needs to be considered as positive time preference is desirable because of opportunity costs; value of a dollar today versus the future, and uncertainty of the future. Thus, a discounting rate of 3% was applied to discount future costs to present value (Drummond et al, 2005). As major adverse events are rare and literature indicated that costs are not significantly affected by including or excluding major adverse events, (Palomaki et al. 2009; Grosse 2015), these were excluded from the study.

2.7 Sensitivity analysis

Uncertainties most relevant to the study included positivity rates of the predictive tests for relatives, adherence rates to colonoscopy and discounting rates. Based on literature, a discounting rate of 3% and an adherence rate of 75% were assumed for the base case in Strategy 1 (Drummond et al 2005; Grosse, 2015). According to the DNA database, 27% of relatives tested positive in 2015. However, literature indicated positive test rates of 39% to 50% in studies carried out in high income countries (Grosse, 2015). Sensitivity analysis was, therefore, performed on positivity rates of 30%, 45% and 50%. Adherence rates reported in studies ranged generally from 79% to 88% (Grosse, 2015). However, in a study conducted in South Africa for LS-diagnosed persons, adherence rates as low as 25% was reported (Bruwer et al, 2013). Thus, adherence rates of 85%, 75%, 50% and 25% were analysed. As discount rates applied are according to societal value judgements, and therefore subjective, Drummond et al (2005) recommended that sensitivity analysis be performed on discount rates employed commonly in literature. The Department of Health guidelines recommends a discount rate of 5% and requires that costs should also be
Presented undiscounted (Department of Health; Government Gazette No. 36118). Hence, discount rates of 0% and 5% were used for the sensitivity analysis.

Approval was obtained from the University of Cape Town Human Research Ethics Committee (HREC REF: 781/2015) and the relevant Provincial Department of Health authorities. The study was self-funded and was conducted as part of the requirements to complete the degree for a Master in Public Health: Health Economics at UCT.

3. Results

Analysis of 40 probands and 934 relatives resulted in 146 individuals and 2,706 colonoscopies identified as per Strategy 1 and 12 individuals and 267 colonoscopies as per Strategy 2. Accommodating for the general population mortality rate, 2,671 colonoscopies were estimated for Strategy 1 and 264 colonoscopies were estimated for Strategy 2. The average age of persons in Strategy 1 and 2 were 38 years and 39 years, respectively. Just over 83% of persons in Strategy 1 and 100% in Strategy 2 required annual colonoscopy screening. For Strategy 1, the number of FDRs per proband was 2.93 and for Strategy 2, the number of FDRs per LS-positive individual was 2.75.

3.1 Cost Analysis

Table 1 shows the breakdown by category of costs for colonoscopy. Around 82% of the colonoscopy costs constituted staff (56%) and equipment (26%) costs. The rest of the costs contributed, individually, less than 4% towards the total cost of colonoscopy.
Table 1: Annual and unit cost by category for colonoscopy presented in 2016 Rand and US $

<table>
<thead>
<tr>
<th>CATEGORY OF COST</th>
<th>ANNUAL COST (n=2347) Rand</th>
<th>US $</th>
<th>UNIT COST Rand</th>
<th>US $</th>
<th>% OF TOTAL COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Staff</td>
<td>4 464 949.62</td>
<td>301 075.50</td>
<td>1 902.41</td>
<td>128.28</td>
<td>56.05%</td>
</tr>
<tr>
<td>Equipment</td>
<td>2 106 100.49</td>
<td>142 016.22</td>
<td>897.36</td>
<td>60.51</td>
<td>26.44%</td>
</tr>
<tr>
<td>Building (Construction)</td>
<td>280 419.00</td>
<td>18 908.90</td>
<td>119.48</td>
<td>8.06</td>
<td>3.74%</td>
</tr>
<tr>
<td>Consumables</td>
<td>275 891.06</td>
<td>18 603.58</td>
<td>117.55</td>
<td>7.93</td>
<td>3.46%</td>
</tr>
<tr>
<td>Overheads &amp; Housekeeping</td>
<td>273 704.01</td>
<td>18 456.10</td>
<td>116.62</td>
<td>7.86</td>
<td>3.44%</td>
</tr>
<tr>
<td>Laboratories</td>
<td>232 029.87</td>
<td>15 645.98</td>
<td>98.86</td>
<td>6.67</td>
<td>2.91%</td>
</tr>
<tr>
<td>Hospital Admin Services</td>
<td>162 109.41</td>
<td>10 931.18</td>
<td>69.07</td>
<td>4.66</td>
<td>2.03%</td>
</tr>
<tr>
<td>Pharmaceuticals</td>
<td>79 701.31</td>
<td>5 374.33</td>
<td>33.96</td>
<td>2.29</td>
<td>1.00%</td>
</tr>
<tr>
<td>Laundry &amp; Linen Services</td>
<td>53 175.99</td>
<td>3 585.70</td>
<td>22.66</td>
<td>1.53</td>
<td>0.67%</td>
</tr>
<tr>
<td>Furniture Colonoscopy</td>
<td>13 913.84</td>
<td>938.22</td>
<td>5.93</td>
<td>0.40</td>
<td>0.17%</td>
</tr>
<tr>
<td>Furniture Shared</td>
<td>6 927.06</td>
<td>467.10</td>
<td>2.95</td>
<td>0.20</td>
<td>0.09%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>7 966 400.18</strong></td>
<td><strong>3 394.29</strong></td>
<td><strong>228.88</strong></td>
<td></td>
<td><strong>100.00%</strong></td>
</tr>
</tbody>
</table>

Follow-Up Genetic Counselling (Applicable to Strategy 2 only) 

<table>
<thead>
<tr>
<th>GENETIC COUNSELLING</th>
<th>COST PER PATIENT Rand</th>
<th>US $</th>
<th>NUMBER OF PATIENTS / FOLLOW-UP COLONOSCOPIES</th>
<th>TOTAL COST Rand</th>
<th>US $</th>
<th>% OF TOTAL COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONCE-OFF GENETIC COUNSELLING SESSIONS FOR DIAGNOSING LS</td>
<td>579.21</td>
<td>39.07</td>
<td>40</td>
<td>23 168.40</td>
<td>1 562.27</td>
<td>58.92%</td>
</tr>
<tr>
<td>FOLLOW-UP GENETIC COUNSELLING SESSIONS WITH COLONOSCOPY SCREENING PROCEDURE</td>
<td>373.49</td>
<td>25.18</td>
<td>11</td>
<td>4 108.39</td>
<td>277.03</td>
<td>10.45%</td>
</tr>
<tr>
<td><strong>TOTAL COST OF GENETIC COUNSELLING</strong></td>
<td><strong>---</strong></td>
<td><strong>---</strong></td>
<td><strong>---</strong></td>
<td><strong>34 468.79</strong></td>
<td><strong>2 324.26</strong></td>
<td><strong>100.00%</strong></td>
</tr>
</tbody>
</table>

Table 2 presents the genetic counselling costs. About 69% of the genetic counselling costs were due to the initial outlay for genetic testing, while 31% of the costs were due to the follow-up counselling over the lifetime colonoscopy screening period.

Table 2: Costs of genetic counselling for diagnosing Lynch Syndrome for probands and their 1st degree relatives presented in 2016 Rand and US $

<table>
<thead>
<tr>
<th>GENETIC COUNSELLING</th>
<th>COST PER PATIENT Rand</th>
<th>US $</th>
<th>NUMBER OF PATIENTS / FOLLOW-UP COLONOSCOPIES</th>
<th>TOTAL COST Rand</th>
<th>US $</th>
<th>% OF TOTAL COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>ONCE-OFF GENETIC COUNSELLING SESSIONS FOR DIAGNOSING LS</td>
<td>579.21</td>
<td>39.07</td>
<td>40</td>
<td>23 168.40</td>
<td>1 562.27</td>
<td>58.92%</td>
</tr>
<tr>
<td>FOLLOW-UP GENETIC COUNSELLING SESSIONS WITH COLONOSCOPY SCREENING PROCEDURE</td>
<td>373.49</td>
<td>25.18</td>
<td>11</td>
<td>4 108.39</td>
<td>277.03</td>
<td>10.45%</td>
</tr>
<tr>
<td><strong>TOTAL COST OF GENETIC COUNSELLING</strong></td>
<td><strong>---</strong></td>
<td><strong>---</strong></td>
<td><strong>---</strong></td>
<td><strong>34 468.79</strong></td>
<td><strong>2 324.26</strong></td>
<td><strong>100.00%</strong></td>
</tr>
</tbody>
</table>

A total of 22 patients had three IHC tests performed per individual i.e. for MLH1, MSH2 and MSH6 at a cost of R385 ($25) per test. Thus, a total of 66 IHC tests were performed
which amounted to R25 401 ($1 712). No MSI testing was done on any of the patients in the cohort.

The costs for genetic testing for diagnosing probands and their FDRs are shown in Table 3. Common founder mutation tests (screening) were performed on 39 probands. Restriction enzyme digest tests and sequencing tests (quality assurance) were performed on the three patients that tested positive with the common founder test. One proband with a suspicion of a known mutation that was not a founder mutation was diagnosed using sequencing testing for both screening and confirmatory purposes. The total costs for diagnosing all probands amounted to R107 940 ($7 279). Of this cost, 92% was due to the common founder mutation test cost. The weighted average unit cost per proband for confirming diagnosis of LS was R2 698 ($182) whereas the cost to test a relative for a known mutation was R926.12 ($62.45).

Table 3: Cost of genetic testing for diagnosing Lynch Syndrome in probands and their 1st degree relatives presented in 2016 Rand and US $.

<table>
<thead>
<tr>
<th>GENETIC TESTS</th>
<th>COST PER TEST</th>
<th>NUMBER OF TESTS</th>
<th>TOTAL COST</th>
<th>WEIGHTED AVERAGE UNIT COST to diagnose a proband</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rand</td>
<td>US $</td>
<td></td>
<td>Rand</td>
</tr>
<tr>
<td><strong>DIAGNOSING LYNCH SYNDROME IN PROBANDS (n=40)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Founder Mutation</td>
<td>2 534.54</td>
<td>170.91</td>
<td>39</td>
<td>98 847.06</td>
</tr>
<tr>
<td>Digest/Predictive</td>
<td>926.12</td>
<td>62.45</td>
<td>3</td>
<td>2 778.36</td>
</tr>
<tr>
<td>Sequencing</td>
<td>1 263.04</td>
<td>85.17</td>
<td>5</td>
<td>6 315.20</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td>47</td>
<td>107 940.62</td>
</tr>
<tr>
<td><strong>DIAGNOSING LYNCH SYNDROME IN 1st DEGREE RELATIVES (n=11)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digest/Predictive</td>
<td>926.12</td>
<td>62.45</td>
<td>11</td>
<td>10 187.32</td>
</tr>
</tbody>
</table>

A summary of the total costs for conducting genetic testing for the study cohort is shown in Table 4. About 78% (63% for genetic testing + 15% for IHC) of the genetic testing costs were attributable to the tests to diagnose the proband. The predictive testing for the 1st degree relatives only contributed 6% to the total genetic testing costs. The total cost of
R170 805 ($11 517) was the once-off outlay to identify four LS patients and 11 FDRs in this cohort. This cost was constant for all scenarios with different parameters in Strategy 2.

Table 4: Costs by category of genetic testing procedure for diagnosing LS in probands tested between 01 November 2014 to 30 October 2015 and their 1st degree relatives, presented in 2016 Rand and US $

<table>
<thead>
<tr>
<th>GENETIC TESTING DIAGNOSTIC PROCEDURES</th>
<th>NUMBER OF TESTS</th>
<th>UNIT COST Rand</th>
<th>UNIT COST US $</th>
<th>TOTAL COST Rand</th>
<th>TOTAL COST US $</th>
<th>% OF TOTAL COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC (Preliminary test)</td>
<td>66</td>
<td>384.86</td>
<td>25.95</td>
<td>25 400.76</td>
<td>1 712.80</td>
<td>14.87%</td>
</tr>
<tr>
<td>Diagnosing LS in probands</td>
<td>40</td>
<td>2 698.52</td>
<td>181.96</td>
<td>107 940.62</td>
<td>7 278.53</td>
<td>63.20%</td>
</tr>
<tr>
<td>Diagnosing LS in relatives</td>
<td>11</td>
<td>926.12</td>
<td>62.45</td>
<td>10 187.32</td>
<td>686.94</td>
<td>5.96%</td>
</tr>
<tr>
<td>Counselling (Excl F/U Counselling)</td>
<td>*112 sessions</td>
<td>4.49/min</td>
<td>0.30/min</td>
<td>27 276.79</td>
<td>1 862.00</td>
<td>15.97%</td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td></td>
<td></td>
<td>170 805.49</td>
<td>11 517.56</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

*Sessions ranged from 15 minutes to 90 minutes (112 sessions = 6075mins)

Costs for the two screening strategies are reflected in table 5. The average unit cost for the entire genetic testing process to diagnose a proband (IHC, genetic testing, counselling) was estimated as R3 913 ($264). The average unit cost for the entire genetic testing process for diagnosing an FDR (genetic testing and counselling) was estimated as R1 300 ($88). The total cost for Strategy 2 was 92% less than the total cost for Strategy 1, i.e. R 390 308 ($26 318) at discount rate 3% and adherence rate 75% compared to R4 932 718 ($332 617) at discount rate 3%, adherence rate 75% and positivity rate of relatives 45%.

Table 5: Total cost per screening strategy based on utilization, presented in 2016 Rand and US $

<table>
<thead>
<tr>
<th>CATEGORY OF COST</th>
<th>UNIT COST Rand</th>
<th>UNIT COST US $</th>
<th>QTY</th>
<th>TOTAL COST STRATEGY 1 Rand</th>
<th>TOTAL COST STRATEGY 1 US $</th>
<th>TOTAL COST STRATEGY 2 Rand</th>
<th>TOTAL COST STRATEGY 2 US $</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colonscopy</td>
<td>3 394.29</td>
<td>228.88</td>
<td>2 671</td>
<td>9 066 148.59</td>
<td>611 338.41</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>Colonscopy with genetic counselling</td>
<td>3 484.09</td>
<td>234.94</td>
<td>264</td>
<td>--</td>
<td>919 799.76</td>
<td>62 022.91</td>
<td></td>
</tr>
<tr>
<td>Genetic testing cost - proband</td>
<td>3 912.74</td>
<td>263.84</td>
<td>40</td>
<td>--</td>
<td>156 509.60</td>
<td>10 553.58</td>
<td></td>
</tr>
<tr>
<td>Genetic testing cost - relatives</td>
<td>1 299.61</td>
<td>87.63</td>
<td>11</td>
<td>--</td>
<td>14 295.71</td>
<td>963.97</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td></td>
<td></td>
<td>9 066 148.59</td>
<td>611 338.41</td>
<td>1 090 605.02</td>
<td>73 540.46</td>
</tr>
<tr>
<td>*TOTAL COST + ASSUMPTIONS</td>
<td></td>
<td></td>
<td></td>
<td>4 932 718.04</td>
<td>332 617.53</td>
<td>390 308.54</td>
<td>26 318.85</td>
</tr>
</tbody>
</table>

*Assumptions: Strategy 1 - Discount rate 3%; Adherence rate 75%; Strategy 2 - Discount rate 3%; Adherence rate 75%, Positivity rate of relatives 45%
3.2 Base Case Analysis

According to scenarios reported in literature, the base case was defined as colonoscopy screening only (Strategy 1) with an adherence rate of 75% and a discount rate of 3% (Snowsill et al 2014; Grosse 2015). The total cost for the base case amounted to R4 932 718 ($332 618). The base case was compared with all combinations of the following parameters: discount rates of 0%, 3%, and 5%; adherence rates of 25%, 50%, 75% and 85%; and positivity rates of relatives of 30%, 45% and 50% (see Part D: Appendices S5 Table). Irrespective of the combination of parameters applied to Strategy 2, the costs for Strategy 2 remained between 89% and 96% less than the base case (Strategy 1). Additionally, with the lowest adherence rate (25%) applied to Strategy 1 and the highest adherence rate 85% and positivity rate of relatives of 50% applied to Strategy 2, Strategy 2 still remained less costly.

3.3 Sensitivity Analysis

One-way sensitivity analysis was conducted to assess the influence of the various parameters on the cost difference between the two screening options. Figure 1 depicts the adherence rates, discount rates and positivity rates of relatives on the difference in cost estimates from the base case. The differences in cost estimates between the two strategies were not significantly sensitive to any of the parameters applied. The cost difference for Strategy 2 remained between 90% and 95% less than the cost estimates for Strategy 1.
4. Discussion

This study has produced evidence that, for potential LS individuals and manifesting-LS individuals, colonoscopy screening with genetic testing (Strategy 2) is substantially less costly than offering colonoscopy screening only (Strategy 1). The total cost for Strategy 2 was 92% less than the total cost for Strategy 1, i.e. R390 308 ($26 319) compared to R4 932 718 ($332 617). The base case analysis and one-way sensitivity analysis showed that this vast cost difference between Strategy 1 and 2 was not influenced by changes in discount rates, adherence rates and positivity rates of relatives. Strategy 2 also allows for high risk individuals to be identified to receive colonoscopy and thus, resources would be focused appropriately. In addition, low risk individuals would not be exposed to hazardous, invasive procedures unnecessarily. Furthermore, patients in this cohort tested positive for
MLH1 and MSH2 mutations and the highest risks for cancer (40% to 70%), are associated with individuals with mutations in these two genes (Bonadona et al. 2011; Steinke et al. 2013; Vasen et al. 2013; Giardiello et al. 2014).

The Numbers Needed to Treat (NNT) for identifying a mutation in a proband was 10. Thus, to identify one patient it would cost R39 127 ($2 638) once off. We can translate this as R39 127 ($2 638) to exclude nine patients from the physical, psychological and financial implications of lifetime colonoscopy screening; while identifying the correct person who will benefit from colonoscopy. Furthermore, the cost of R39 127 ($2 638) for genetic testing would be offset easily by the savings incurred by not performing lifetime colonoscopies for nine patients. Similarly, the NNT for FDRs would range from 2 (50% positivity) to 3 (30% positivity). Thus, to identify one positive relative would cost between R2 600 ($175) to R3 900 ($262). This cost would exclude one in every two FDRs tested to one in every three FDRs tested from lifetime colonoscopy screening. Though the initial outlay to identify a mutation in a proband is high, the benefits for the relatives are acquired at a much lower cost.

The common founder genetic test made up 91% of the costs of identifying a mutation in a proband and about 63% of the overall costs for the genetic testing procedure. Influencing the price of the common founder test would significantly influence the total cost of genetic testing. The number of colonoscopies was the cost driver in the screening process for Strategy 1 and this was influenced by adherence to colonoscopy screening. For Strategy 2, the cost driver(s) (genetic testing and / or number of colonoscopies) were influenced by adherence to colonoscopy as well as the proportion of relatives that tested positive. The total cost for genetic testing for the cohort was fixed at R170 805 ($11 518). At a mutation positive rate of relatives of 45% and an adherence of 75%, genetic testing contributed 44% and colonoscopy 56% to the total costs; whereas at a mutation positive rate of relatives of
30% and adherence of 25%, genetic testing contributed 78% and colonoscopy 22% to total costs. This shows that the fewer the colonoscopies, the greater the proportion of the cost for genetic testing. Genetic testing without colonoscopy screening provides no benefit in reducing the risk of colorectal cancer and therefore would be a waste of resources. Thus, the less colonoscopies performed, the greater the proportion of loss in benefit of the total cost. Uptake of colonoscopy screening amongst mutation carriers were reported as around 79% to 88% in studies performed in high income countries (Grosse, 2015). However, a South African study reported adherence rates for LS-diagnosed persons of 25% over a 5 year period (Bruwer et al., 2013). As access to colonoscopy screening in South Africa is generally limited to tertiary care hospitals in the public sector, this may be one of the reasons for the low adherence rate. A well-functioning, accessible colonoscopy programme is, therefore, important in order to optimise the benefits of genetic testing.

Literature reported that the proportions of FDRs that tested positive for a mutation ranged from 39% to 50% (Grosse, 2015; Snowsill 2014). Also, family mutation prevalence in FDRs is assumed at 50% due to autosomal dominant inheritance of LS (Grosse, 2015). The proportion of relatives on the DNA database that tested positive for a mutation in 2015 was 27%. This may be an under detection of mutations as the Division of Human Genetics: UCT test predominantly for founder mutations in \textit{MHL1} and \textit{MSH2} genes. Also, genetic testing in the public sector is not an established practice and many relatives may not have the opportunity to get tested. The greater the proportion of positive relatives identified to the proband, the greater the benefit of genetic testing as predictive testing is less expensive than diagnosing a proband and the relative is more likely to be ‘at risk’ (i.e. not affected by cancer yet). Thus, to improve the benefit / value for money of a genetic testing programme, testing of relatives should be strongly encouraged and facilitated.
Staff executing colonoscopy contributed 56% to the total cost of colonoscopy. In the Western Cape colonoscopies are performed by sub-specialists and this significantly inflates the cost of colonoscopy. Furthermore, the demand for colonoscopy outweighs the supply of gastroenterologists. Data exists for non-physicians providing simple endoscopy procedures safely and effectively (Day et al, 2014); however, published data on non-physician colonoscopy programmes is lacking (Ruco et al, 2016). This emphasises the importance of selecting appropriate persons for colonoscopy screening and avoiding unnecessary colonoscopies. An annual cost of R3 484 ($235) per patient for colonoscopy can be translated to about R290 ($20) per month to reduce the risk of colorectal cancer by 62% to 72% (Palomaki et al. 2009; Giardiello et al. 2014; Snowsill et al 2014; Gross, 2015). Compared with other tertiary treatments, this does not appear excessive. Conclusive evidence on whether colonoscopy screening every 1 to 2 years is superior to 2 to 3 years has not been established (Grosse, 2015; Vasen et al. 2013). Employing biennial colonoscopy would reduce the total cost of colonoscopies by almost half in both strategies as more than 80% of individuals in Strategy 1 and 100% individuals in Strategy 2 formed part of the annual colonoscopy regimen.

Our study assumed that all persons identified for genetic testing would accede to testing. Based on this assumption, the number of FDRs tested per proband was 2.75 which is consistent with data reported in literature (Grosse 2015; Snowsill et al 2014). In addition, Bruwer et al. (2013) reported high uptake rates of 97% and 74% for siblings and children, respectively. Furthermore, predictive genetic testing of FDRs contributed only 6% to the total costs of genetic testing. Thus, the uptake for genetic testing would not significantly affect the total cost for Strategy 2.

The cost of repeat colonoscopy, polypectomy, bleeding and biopsy was included in the cost estimate of colonoscopy. Major complications such as perforations are rare and were

5. Conclusion

Colonoscopy screening for potential and confirmed LS patients were substantially less costly when combined with genetic testing. Implementing colonoscopy screening with genetic testing would, thus, support the efficient use of health care resources.

6. Limitations

There is potential for generalisability in the public sector across South Africa as practices, salary packages and procurement contracts are usually aligned. However, patient profiles may differ. The study assumed general population mortality rates and did not include risks of other rarer cancers that are part of the LS spectrum and therefore the costs may be overestimated. This assumption is not expected to affect the direction of the results as the incidence of other cancers would be higher in the LS-diagnosed group (Strategy 2) and thus potential increased mortality rate in this group. Furthermore, in a cost-utility study Snowsill et al. (2015) reported that costs of surveillance of gynaecological cancer and other cancers associated with LS were excluded due to the lack of evidence of effectiveness of surveillance in these cancers (Snowsill et al., 2015). Strategies that included MSI testing, BRAF V600E and MLPA were not evaluated. At the time of the study, Sanger sequencing was less costly than MLPA and was the test used for quality assurance. As MSI was not requested for this cohort, the cost impact of MSI is assumed to be minimal as it would be once-off and required infrequently. The results of the genetic testing indicated that \textit{BRAF}
*V600E* would not have been of value as all *MLH1* genes had positive mutations. IHC testing identified mismatch repair mutations in *MSH6* in 2 individuals and these patients tested negative for the common founder mutations (screening test). This study has provided evidence of cost implications for genetic testing and colonoscopy screening; however, further research on the effectiveness of such programmes would be of value.
References


Finance Department: Groote Schuur Hospital, 2015. Basic Accounting System (BAS) report. Groote Schuur Hospital


Somda, Z.C., Meltzer, M.I., Perry, H.N. 2007. SurvCost 1.0: a manual to assist country and district public health officials in estimating the cost of the implementation of IDSRS. CDCP. Department of Health and Human Services. USA.


PART D: APPENDICES

A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a tertiary hospital, South Africa

1. Supplementary material
   - Cost allocation and calculations tables
   - Analysis of probands and relatives
   - Base Case analysis table
2. Consent form
3. Letter of approval from Research Ethics Committee
4. Permission to proceed with research – Groote Schuur hospital
5. Change of title
6. Instructions for author for journal article
1. SUPPLEMENTARY MATERIAL – COST ALLOCATIONS AND CALCULATIONS

Examples of Allocation of Costs – MS Excel ® data collection and cost analysis tools

S1 Table: Example: Personnel costs estimation per unit (minute) for colonoscopy (or genetic testing)

<table>
<thead>
<tr>
<th>Staff Rank</th>
<th>Annual CTC</th>
<th>No of working days per year: 22dysx12mths</th>
<th>Cost per day</th>
<th>Number of hours worked per day</th>
<th>Number of working minutes per day (8x60)</th>
<th>Unit cost: Cost per minute</th>
<th>Time spent on task</th>
<th>Total cost</th>
<th>Source</th>
<th>Documents</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total annual shared staff cost for e23

Proportion factor: (number of colonoscopies/E23 pts visits)

Total annual shared hospital management cost for e23

Proportion factor: (number of staff involved colonoscopy/number of hospital staff)

S2 Table: Example: Estimation of building cost for colonoscopy (or genetic test)

<table>
<thead>
<tr>
<th>Building area</th>
<th>Value</th>
<th>Proportion allocation</th>
<th>Estimated building cost of usable area</th>
<th>Annuited cost (for 30yrs, rate 3%, factor 19.6)</th>
<th>Source for measurement &amp; valuation</th>
<th>Cost per colonoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shared ward area (m²)</td>
<td>Estimated building cost (rand/m²)</td>
<td>Colonoscopy pts/ total ward pts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colonscopy Usable Area</td>
<td>Estimated building cost (rand/m²)</td>
<td>100%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory area</td>
<td>Cost of lab</td>
<td>Proportion time used</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

S3 Table: Example: Estimation of equipment cost for colonoscopy (or genetic test)

<table>
<thead>
<tr>
<th>Description</th>
<th>Qty</th>
<th>Unit Cost</th>
<th>% usable time</th>
<th>Total costs</th>
<th>Working life, years</th>
<th>Annual discount rate 3%</th>
<th>Annual equivalent cost</th>
<th>Annual maintenance (8%)</th>
<th>Total annual cost</th>
<th>Cost per colonoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrical Surgical Unit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cost / number of colonoscopies</td>
</tr>
<tr>
<td>Olympus scope</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Centrifuge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Apply 65% and 75% efficiency rate to genetic testing equipment.

S4 Table: Example: Estimation of consumables and reagents for genetic testing

<table>
<thead>
<tr>
<th>Item name</th>
<th>Original container qty (e.g. 5L; 500g)</th>
<th>Original container qty cost</th>
<th>Cost p/Unit</th>
<th>Qty Used for test</th>
<th>Cost p/test</th>
<th>No of Tests p/a</th>
<th>Total Cost p/a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclease free H2O 1L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100mM dNTP set</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sense primer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antisense primer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See Part C: Journal Article – page 10

PART D: Appendices
2. SUPPLEMENTARY MATERIAL: ANALYSIS OF PROBANDS AND RELATIVES

S1 Fig: Demographic analysis per screening Strategy 1 of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives

STRATEGY 1: COLONOSCOPY SCREENING FOR POTENTIAL LS INDIVIDUALS

- 41 patient (proband) samples received for unknown mutation
- 1 patient - duplication
- 40 probands / samples
- 974 patients plus relatives

Family size
Average: 974/40 = 24.35
Range: 78 (6 to 84)
Median: 25
Mode: 22

Demographic analysis per screening Strategy 1 of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives:

- STRATEGY 1: COLONOSCOPY SCREENING FOR POTENTIAL LS INDIVIDUALS
- 41 patient (proband) samples received for unknown mutation
- 1 patient - duplication
- 40 probands / samples
- 974 patients plus relatives

Demographic analysis per screening Strategy 1 of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives:

- STRATEGY 1: COLONOSCOPY SCREENING FOR POTENTIAL LS INDIVIDUALS
- 41 patient (proband) samples received for unknown mutation
- 1 patient - duplication
- 40 probands / samples
- 974 patients plus relatives

S1 Fig. illustrates the analysis for Strategy 1 of the probands and their relatives in terms of relationship, gender, age, etc. A total of 146 (14 +132) persons were selected for intensive colonoscopy.

See part A: Protocol – Pages 14, 15 & 17

See Part C: Journal Article – Page 7
S2 Fig: Demographic analysis per screening Strategy 2 of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives

STRATEGY 2: GENETIC TESTING FOR LS FOLLOWED BY COLONOSCOPY FOR LS POSITIVE INDIVIDUALS

41 patient (proband) samples received for unknown mutation

1 patient - duplication

40 probands / samples

4 tested positive for mutation

151 probands + relatives identified

exclude deaths, spouses, spouse family, <25 years old, >60 yrs

36 females

13 males

1 unknown

22 females

13 males

1 unknown

Family size
Average: 151/40 = 3.78
Range: 70 (14 to 84)
Median: 26.5
Mode: none

25 - 29 years old
n = 6

Average eligible persons* per proband
36/40 = 0.90

30 - 60 years old
n = 30

Proband relatives in relation to proband

include proband & 1st degree relatives
exclude 1 x total colectomy patient

0 patients for intensive colonoscopy screening

Average first degree relative per positive proband
11/4 = 2.75

Average age = 39 years

12 patients for intensive colonoscopy screening

S2 Fig. illustrates the analysis for Strategy 2 of the probands and their relatives in terms of relationship, gender, age, etc. A total of 12 persons were selected for intensive colonoscopy.

See part A: Protocol – Pages 14, 15 & 17

See Part C: Journal Article – page 7
S3 Fig: Analysis per screening strategy of probands on the DNA database that were tested for LS between 01 November 2014 and 30 October 2015, and their relatives

STRATEGY 1: COLONOSCOPY SCREENING ONLY

- Patient present with CRC
  - <50yrs / right-sided lesion / crohns-like response

- REVISED BETHESDA CRITERIA FULFILLED (Proband)
  - 40 (41 - 1 patient duplicated)

- PROBAND AND 1ST DEGREE RELATIVES

- INTENSIVE COLONOSCOPY SCREENING
  - 146

STRATEGY 2: GENETIC TESTING FOR LS FOLLOWED BY COLONOSCOPY FOR LS POSITIVE INDIVIDUALS

- Patient present with CRC
  - <50yrs / right-sided lesion / crohns-like response

- REVISED BETHESDA CRITERIA FULFILLED (Proband)
  - 40 (41 - 1 patient duplicated)

- IHC not done
  - 18

- IHCNEGATIVE
  - 16

- IHCNEGATIVE Not for intensive colonoscopy screening
  - 36

- IHCPOSITIVE
  - 6

- 18

- 16

- 5

- 1

- 36 negative

- 3 positive

- 1 positive

- PREDICTIVE/DIGEST TEST
  - 3

- SEQUENCING TEST
  - 3

- 3 positive

- PREDICTIVE GENETIC TESTING FOR ALL FIRST DEGREE RELATIVES
  - 11

- Exclude probands with total colectomies & deaths

- POSITIVE FIRST DEGREE RELATIVES PLUS POSITIVE PROBANDS (1)

- INTENSIVE COLONOSCOPY SCREENING (12)

CRC - Colorectal cancer

* includes 3 patients from the private sector - IHC assumed done

** 6 positive patients: 3 patients with MLH1 mismatch; 2 patients with MSH6 mismatch; 1 patient with MSH2 mismatch (private sector)

S3 Fig: illustrates the analysis for Strategy 1 and 2 of probands in terms of the tests performed and the results; plus the relevant first degree relatives of the LS positive probands.

See part A: Protocol – Pages 14, 15 & 17

See Part C: Journal Article – page 8

PART D: Appendices
S5 Table: Percentage difference in total costs of colonoscopy screening between the base case and Strategy 1 and 2 at various discount rates, adherence rates and positivity rates of relatives, presented in 2016 Rand and US $.

<table>
<thead>
<tr>
<th>DISCOUNT RATES</th>
<th>STRATEGY 1: COLONOSCOPY SCREENING FOR AT RISK PATIENTS</th>
<th>STRATEGY 2: GENETIC TESTING AND COLONOSCOPY SCREENING FOR LS DIAGNOSED PATIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ADHERENCE RATE 85% % change in base case</td>
<td>ADHERENCE RATE 75% % change in base case</td>
</tr>
<tr>
<td>No discount</td>
<td>56%</td>
<td>38%</td>
</tr>
<tr>
<td>Discount rate 3%</td>
<td>13%</td>
<td>-17%</td>
</tr>
<tr>
<td>Discount rate 5%</td>
<td>-6%</td>
<td>-17%</td>
</tr>
</tbody>
</table>

* Percentage change in base case: [(Cost of alternate case - Cost of base case) / Cost of base case] x 100
¥ Base case: estimated at a discount rate 3%, adherence rate 75%

S6 Table shows that Strategy 2 (colonoscopy screening combined with genetic testing) costs between 89% and 96% less than Strategy 1 (colonoscopy screening only), irrespective of the scenario (parameters) applied. See Part C: Journal Article – pg 18.
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM

TITLE OF THE RESEARCH PROJECT:

PRINCIPAL INVESTIGATOR: Dr Edina Sinanovic, Director: School of Public Health & Family Medicine: Health Economics Unit, University of Cape Town (UCT), Anzio Road, Observatory.

CO-INVESTIGATOR / INTERVIEWER: Ms Yasmina Johnson (MPH: Masters Student), Pharmacy Services, 14th floor, 04 Dorp Street, Cape Town, 8001
CONTACT NUMBER: Office Hours: 021 483 6198 24 hour number: 084 417 5137

CO-INVESTIGATORS:
• Prof J Moodley, Cancer Research: Faculty of Health Science; and School of Public Health & Family Medicine, UCT, Anzio Road, Observatory
• Prof P Goldberg, Head: E22 Colorectal Unit, Groote Schuur Hospital, Observatory

I would like to invite you to take part in a research study. The details of the study are presented below. Please take some time to read the information which will enable you to decide whether you would like to participate or not.

It is very important that you understand what the research involves and how you will be involved in the research. If there is any part of the information / study that you do not understand clearly, please feel free to ask the person interviewing you to explain this to you.

Your decision to take part in the research is entirely voluntary. This means that you are free to decide not to participate and you may also withdraw from the study at any point during the study. You do not have to provide a reason for not participating or withdrawing from the study. If you decide not to take part in the study or to withdraw from the study, this will not affect you negatively in any way.
This study has been approved by the Health Research Ethics Committee at the University of Cape Town and will be conducted according to the ethical guidelines and principles of the international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for Research.

1. Introduction
Lynch Syndrome is a genetic disorder that increases an individual’s risk to develop colorectal cancer and other cancers. Colorectal cancer is generally asymptomatic (no obvious symptoms present) until it has reached an advanced stage and thus an effective screening programme is important for early detection and successful management of colorectal cancer. Colonoscopy is the only screening programme that has proved to be effective for these individuals.

Furthermore, genetic testing allows for accurate prediction of individuals at high risk of colorectal cancer. Thus, using genetic testing, individuals at high risk who will benefit most from colonoscopy screening can be identified while those at low risk of disease can be excluded from potentially invasive screening procedures.

Preventing or delaying cancer onset, by appropriate screening strategies, will have social as well as economic benefits for the country. It is therefore important to establish the affordability of such a programme.

2. What is this research study all about?
The aim of the study is to estimate the cost of two screening options for colorectal cancer for individuals with a suspected or confirmed Lynch Syndrome diagnosis. Thus, information related to the cost of providing colonoscopy and genetic services will be collected and analysed.

3. Why have you been invited to participate?
You have been asked to participate in the study because you are involved in providing the service, have experience regarding the service or have access to information and costs related to the service.

4. What will your responsibilities be?
You will be asked to provide information regarding the logistics, utilisation, procedures or costs of providing the service.

5. What will the investigator’s / researcher’s responsibilities be?
The investigator / researcher will obtain formal permission to access and use the information that you provide as well as ethics approval. The researcher will organise suitable meeting times with you to obtain the study information.

6. How long will you be expected to participate in the study?
You may be expected to participate until 28 December 2016 when the study is anticipated to be completed. However, your involvement will only be related to the data noted in point 4.

7. Will you benefit from taking part in this research?
There will be no direct clinical benefit to you from participating in the study. However, the results of the study will inform policy-makers regarding affordability of the screening service, as well as providing insight into prioritising and allocation of resources.

8. Are there any risks involved in your taking part in this research?
No risks to you are anticipated as the research focuses on analysing data for costing purposes and no human subjects are directly involved.

9. Will you be paid to take part in this study and are there any costs involved?
You will not receive any payment for participating in the study. You will also not have any expenses while participating in the study. The study is self-funded by the researcher.

10. Who will have access to the information that you provide?
The study team will have access to the information that you provide. Regulatory authorities and members of the research ethics committee will have access to the information in order to check that the study was conducted properly.

Information will be captured under unique identifiers (codes) and no names will appear on forms or in the database. No identifiers will be used in the analysis or appear in any publication or report. All electronic data will be password protected and accessible only to the study team. Paper forms will be filed and stored in a locked cabinet.

Following completion of the study, it will be submitted for the Masters in Public Health: Health Economics degree. The findings of the study will also be submitted to the relevant Department of Health officials in the Western Cape, UCT Human Genetics department, Groote Schuur hospital and persons that participated in the study. A manuscript will be drafted for publication.

11. Is there anything else that you should know?

PART D: Appendices
• You can contact the researcher, Yasmina Johnson, at Tel 021 484-6198 or 084 415 7137 if you have any further queries or encounter any problems.

• You can contact the UCT Health Research Ethics Committee at 021-21 406 6492 if you have any concerns or complaints that have not been adequately addressed by the research team.

• You will be provided with a copy of this information and consent form for your own records.

12. Do you have any questions that you wish to ask?

________________________________________________________________________

DECLARATION BY INFORMANT / INTERVIEWEE:

By signing below, I …………………………………………………. agree to take part in a research study entitled:

A cost analysis of providing colonoscopy screening versus colonoscopy screening plus genetic testing for adults with Lynch Syndrome in a tertiary level care hospital, South Africa.

I declare that:

• I have read and understood the information and consent form.

• I have had an opportunity to ask questions and all my questions have been answered satisfactorily.

• I understand that taking part in this study is voluntary and that I have not been coerced in any way to take part.

• I may choose to withdraw from the study at any time and will not be penalised or prejudiced in any way.

Signed at (place) .................................................. on (date) .................................

Signature of participant: __________________________

DECLARATION BY INVESTIGATOR:
I (name) ……………………………………………………… declare that:

- I explained the information in this document to …………………………………
- I encouraged him/her to ask questions and took adequate time to explain and answer these questions.
- I am satisfied that he/she understands all aspects of the research adequately, as discussed in this information leaflet and consent form.

Signed at (place) ……………………………………………… on (date) …………………………………

Signature of investigator: _______________
26 November 2015

HREC REF: 781/2015

Dr E Sinanovic
Health Economics Division
School of Public Health & Family Medicine
FHS

Dear Dr Sinanovic

PROJECT TITLE: A COST ANALYSIS OF PROVIDING COLONOSCOPY SCREENING VERSUS COLONOSCOPY SCREENING PLUS GENETIC TESTING FOR ADULTS WITH LYNCH SYNDROME IN A TERTIARY LEVEL CARE HOSPITAL, SOUTH AFRICA.- Masters candidate Yasmina Johnson

Thank you for your response letter, addressing the issues raised by the Human Research Ethics Committee (HREC).

It is a pleasure to inform you that the HREC has formally approved the above-mentioned study.

Approval is granted for one year until the 30th November 2016.

Please submit a progress form, using the standardised Annual Report Form if the study continues beyond the approval period. Please submit a Standard Closure form if the study is completed within the approval period. (Forms can be found on our website: www.health.uct.ac.za/fhs/research/humanethics/forms)

We acknowledge that the following student:- Yasmina Johnson is also involved in this project.

Please quote the HREC reference no in all your correspondence.

Please note that the ongoing ethical conduct of the study remains the responsibility of the principal investigator.

Yours sincerely

PROFESSOR M BLockman
Chairperson, FHS Human Research Ethics Committee
Federal Wide Assurance Number: FWA00001637.
Institutional Review Board (IRB) number: IRB00001938

Hrec/ref: 781/2015
Ms. Y. Johnson  
Pharmacy Services  
Western Cape Government Health  
4 Dorp Street  
CAPE TOWN  
8001

E-mail: Yasmina.Johnson@westerncape.gov.za

Dear Ms. Johnson,

RESEARCH PROJECT: A Cost Analysis of Providing Colonoscopy Screening Versus Colonoscopy Screening Plus Genetic Testing For Adults With Lynch Syndrome in the Western Cape, South Africa

Your recent letter to the hospital refers.

You are hereby granted permission to proceed with your research.

Please note the following:

a) Your research may not interfere with normal patient care.
b) Hospital staff may not be asked to assist with the research.
c) No hospital consumables and stationary may be used.
d) **No patient folders may be removed from the premises or be inaccessible.**
e) Please introduce yourself to the person in charge of an area before commencing.
f) Please discuss the study with the HOD before commencing.
g) Please provide the research assistant/field worker with a copy of this letter as verification of approval.
h) Confidentiality must be maintained at all times.

I would like to wish you every success with the project.

Yours sincerely,

DR BERNADETTE EICK  
CHIEF OPERATIONAL OFFICER  

Date: 10 December 2015

C.C. Mr. L. Naidoo  
Professor E. Weimann  
Professor S. Thomson

G46 Management Suite, Old Main Building, Observatory 7925  
Private Bag X, Observatory, 7935

Tel: +27 21 404 6288 Fax: +27 21 404 6125  
www.capegateway.gov.za
University of Cape Town
Faculty of Health Sciences
Form D9: Approval for Change of Title

Please complete and return to Vuyi Mgqwi (Vuyi.Mgqwi@uct.ac.za) in the Postgraduate Office

Name and student no: Yasmina Johnson JHNYSO01
Degree name (e.g. MSc[Res] in Physiology): MPH: Health Economics
Email address for correspondence: Yasmina.Johnson@westerncape.gov.za
Student signature: ____________________________ Date: 09/09/2018

Qualifications
B.Pharm

Old Title
A cost analysis of providing colonoscopy screening versus colonoscopy screening plus genetic testing for adults with Lynch Syndrome in a tertiary level care hospital, South Africa

Proposed new title
A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a tertiary hospital, South Africa

Proposed title change supported by Departmental Research Committee (DRC)

Name of Chair, Department Research Committee: Prof. Jonna Hemmes
Signature: ____________________________ Date: 16/2/2017

Please give reason for the need for to change your thesis/dissertation title:

Initial title is too long and complex. The new title is shorter and provides sufficient detail regarding the study.

(If you require more space than this then please attach a separate page)

I support / do not support the thesis/dissertation title change as requested by this student

Supervisor name and signature: Name: Prof. Edina Simovnic Signature: ____________________________ Date: 08 February 2017

I recommend / do not recommend the thesis/dissertation title change as requested by this student

HOD name and signature: Name: Prof. Mohamed Jeabby Signature: ____________________________ Date: 15/02/2017

I approve / do not approve the thesis/dissertation title change as requested by the above student

Deputy Dean: Postgraduate Affairs: Name: ____________________________ Signature: ____________________________ Date: ____________________________

For office use:

Received by: Name: ____________________________ Date: ____________________________
Collected on PeopleSoft: Name: ____________________________ Date: ____________________________
Enter in #12C: Name: ____________________________ DC no. PG med Date: ____________________________

PART D: Appendices
Submission Guidelines PLoS

Style and Format

File format  
Manuscript files can be in the following formats: DOC, DOCX, RTF, or PDF. Microsoft Word documents should not be locked or protected.

LaTeX manuscripts must be submitted as PDFs. Read the LaTeX guidelines.

Length  
Manuscripts can be any length. There are no restrictions on word count, number of figures, or amount of supporting information.

We encourage you to present and discuss your findings concisely.

Font  
Use a standard font size and any standard font, except for Symbol font.

Headings  
Limit manuscript sections and sub-sections to 3 heading levels. Make sure heading levels are clearly indicated in the manuscript text.

Layout  
Manuscript text should be double-spaced.

Do not format text in multiple columns.

Page and line numbers  
Include page numbers and line numbers in the manuscript file.

Footnotes  
Footnotes are not permitted. If your manuscript contains footnotes, move the information into the main text or the reference list, depending on the content.

Language  
Manuscripts must be submitted in English.

You may submit translations of the manuscript or abstract as supporting information. Read the supporting information guidelines.

Abbreviations  
Define abbreviations upon first appearance in the text.

Do not use non-standard abbreviations unless they appear at least three times in the text.

Keep abbreviations to a minimum.

Reference style  
PLOS uses “Vancouver” style, as outlined in the ICMJE sample references.

See reference formatting examples and additional instructions below.

Equations  
We recommend using MathType for display and inline equations, as it will provide the most reliable outcome. If this is not possible, Equation Editor is acceptable.

Avoid using MathType or Equation Editor to insert single variables (e.g., “a² + b² = c²”), Greek or other symbols (e.g., β, Δ, or ′ [prime]), or mathematical operators (e.g., x, ≥, or ±) in running text. Wherever possible, insert single symbols as normal text with the correct Unicode (hex) values.

Do not use MathType or Equation Editor for only a portion of an equation. Rather, ensure that the entire equation is included. Avoid “hybrid” inline or display equations, in which part is text and part is MathType, or part is MathType and part is Equation Editor.

Nomenclature  
Use correct and established nomenclature wherever possible.

- **Units of measurement**  
  Use SI units. If you do not use these exclusively, provide the SI value in parent each value. Read more about SI units.

- **Drugs**  
  Provide the Recommended International Non-Proprietary Name (rINN).

- **Species names**  
  Write in italics (e.g., *Homo sapiens*). Write out in full the genus and species, both of the manuscript and at the first mention of an organism in a paper. After first letter of the genus name followed by the full species name may be used (e.g., *H. sapiens*)

- **Genes, mutations, genotypes, and alleles**  
  Write in italics. Use the recommended name by consulting the appropriate gene nomenclature database (e.g., HUGO for human genes). It is sometimes advisable to use the synonyms for the gene the first time it appears in the text. Gene prefixes such as oncogenes or cellular localization should be shown in roman typeface (e.g., MYC).
Manuscript Organization

Manuscripts should be organized as follows. Instructions for each element appear below the list.

**Beginning section** *The following elements are required, in order:*

- Title page: List title, authors, and affiliations as first page of manuscript
- Abstract
- Introduction

**Middle section** *The following elements can be renamed as needed and presented in any order:*

- Materials and Methods
- Results
- Discussion
- Conclusions (optional)

**Ending section** *The following elements are required, in order:*

- Acknowledgments
- References
- Supporting information captions (if applicable)

**Other elements**

- Figure captions are inserted immediately after the first paragraph in which the figure is cited. Figure files are uploaded separately.
- Tables are inserted immediately after the first paragraph in which they are cited.
- Supporting information files are uploaded separately.

Parts of a Submission

**Title**

Include a full title and a short title for the manuscript.

<table>
<thead>
<tr>
<th>Title</th>
<th>Length</th>
<th>Guidelines</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full title</td>
<td>250 characters</td>
<td>Specific, descriptive, concise, and comprehensible to readers outside the field</td>
<td>Impact of cigarette smoke exposure on innate immunity: <em>A Caenorhabditis elegans</em> model</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Solar drinking water disinfection (SODIS) to reduce childhood diarrhoea in rural Bolivia: A cluster-randomized, controlled trial</td>
</tr>
<tr>
<td>Short title</td>
<td>100 characters</td>
<td>State the topic of the study</td>
<td>Cigarette smoke exposure and innate immunity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SODIS and childhood diarrhoea</td>
</tr>
</tbody>
</table>

Titles should be written in sentence case (only the first word of the text, proper nouns, and genus names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic reviews, or meta-analyses, the subtitle should include the study design.

**Author List**
Authorship requirements

All authors must meet the criteria for authorship as outlined in the authorship policy. Those who contributed to the work but do not meet the criteria for authorship can be mentioned in the Acknowledgments. Read more about Acknowledgments.

The corresponding author must provide an ORCID iD at the time of submission by entering it in the user profile in the submission system. Read more about ORCID.

Author names and affiliations

Enter author names on the title page of the manuscript and in the online submission system.

On the title page, write author names in the following order:

- First name (or initials, if used)
- Middle name (or initials, if used)
- Last name (surname, family name)

Each author on the list must have an affiliation. The affiliation includes department, university, or organizational affiliation and its location, including city, state/province (if applicable), and country.

If an author has multiple affiliations, enter all affiliations on the title page only. In the submission system, enter only the preferred or primary affiliation.

Author names will be published exactly as they appear in the manuscript file. Please double-check the information carefully to make sure it is correct.

Corresponding author

The submitting author is automatically designated as the corresponding author in the submission system. The corresponding author is the primary contact for the journal office and the only author able to view or change the manuscript while it is under editorial consideration.

The corresponding author role may be transferred to another coauthor. However, note that transferring the corresponding author role also transfers access to the manuscript. (To designate a new corresponding author while the manuscript is still under consideration, watch the video tutorial below.)

Only one corresponding author can be designated in the submission system, but this does not restrict the number of corresponding authors that may be listed on the article in the event of publication. Whoever is designated as a corresponding author on the title page of the manuscript file will be listed as such upon publication. Include an email address for each corresponding author listed on the title page of the manuscript.

Author Contributions

Enter all author contributions in the submission system during submission. The contributions of all authors must be described using the CRediT Taxonomy of author roles. Read the policy.

Contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.

PLOS ONE will contact all authors by email at submission to ensure that they are aware of the submission.

Cover letter

Upload a cover letter as a separate file in the online system. The length limit is 1 page.
The cover letter should include the following information:

- Summarize the study’s contribution to the scientific literature
- Relate the study to previously published work
- Specify the type of article (for example, research article, systematic review, meta-analysis, clinical trial)
- Describe any prior interactions with PLOS regarding the submitted manuscript
- Suggest appropriate Academic Editors to handle your manuscript (see the full list of Academic Editors)
- List any opposed reviewers

**Title page**

The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.

**Abstract**

The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a separate field in the submission system.

The Abstract should:

- Describe the main objective(s) of the study
- Explain how the study was done, including any model organisms used, without methodological detail
- Summarize the most important results and their significance
- Not exceed 300 words

Abstracts should not include:

- Citations
- Abbreviations, if possible

**Introduction**

The introduction should:

- Provide background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study
- Define the problem addressed and why it is important
- Include a brief review of the key literature
- Note any relevant controversies or disagreements in the field
- Conclude with a brief statement of the overall aim of the work and a comment about whether that aim was achieved

**Materials and Methods**

The Materials and Methods section should provide enough detail to allow suitably skilled investigators to fully replicate your study. Specific information and/or protocols for new methods should be included in detail. If materials, methods, and protocols are well established, authors may cite articles where those protocols are described in detail, but the submission should include sufficient information to be understood independent of these references.

We encourage authors to submit detailed protocols for newer or less well-established methods as supporting information. Read the supporting information guidelines.

Human or animal subjects and/or tissue or field sampling

PART D: Appendices
Methods sections describing research using human or animal subjects and/or tissue or field sampling must include required ethics statements. See the reporting guidelines for human research, clinical trials, animal research, and observational and field studies for more information.

Data

PLOS journals require authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception.

Large data sets, including raw data, may be deposited in an appropriate public repository. See our list of recommended repositories.

For smaller data sets and certain data types, authors may provide their data within supporting information files accompanying the manuscript. Authors should take care to maximize the accessibility and reusability of the data by selecting a file format from which data can be efficiently extracted (for example, spreadsheets or flat files should be provided rather than PDFs when providing tabulated data).

For more information on how best to provide data, read our policy on data availability. PLOS does not accept references to “data not shown.”

Results, Discussion, Conclusions

These sections may all be separate, or may be combined to create a mixed Results/Discussion section (commonly labeled “Results and Discussion”) or a mixed Discussion/Conclusions section (commonly labeled “Discussion”). These sections may be further divided into subsections, each with a concise subheading, as appropriate. These sections have no word limit, but the language should be clear and concise.

Together, these sections should describe the results of the experiments, the interpretation of these results, and the conclusions that can be drawn.

Authors should explain how the results relate to the hypothesis presented as the basis of the study and provide a succinct explanation of the implications of the findings, particularly in relation to previous related studies and potential future directions for research.

PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors should avoid overstating their conclusions. See the PLOS ONE Criteria for Publication for more information.

Acknowledgments

Those who contributed to the work but do not meet our authorship criteria should be listed in the Acknowledgments with a description of the contribution.

Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to be named.

Do not include funding sources in the Acknowledgments or anywhere else in the manuscript file. Funding information should only be entered in the financial disclosure section of the submission system.

References

Any and all available works can be cited in the reference list. Acceptable sources include:

- Published or accepted manuscripts
- Manuscripts on preprint servers, if the manuscript is submitted to a journal and also publicly available as a preprint

Do not cite the following sources in the reference list:

PART D: Appendices
• Unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or deposit the data in a publicly available database.
• Personal communications (these should be supported by a letter from the relevant authors but not included in the reference list)

References are listed at the end of the manuscript and numbered in the order that they appear in the text. In the text, cite the reference number in square brackets (e.g., “We used the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.

Do not include citations in abstracts or author summaries.

Make sure the parts of the manuscript are in the correct order before ordering the citations.

Formatting references

Because all references will be linked electronically as much as possible to the papers they cite, proper formatting of the references is crucial.

PLOS uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. Additional examples are in the ICMJE sample references.

A reference management tool, EndNote, offers a current style file that can assist you with the formatting of your references. If you have problems with any reference management program, please contact the source company's technical support.

Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases.

<table>
<thead>
<tr>
<th>Source</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accepted, unpublished articles</td>
<td>Same as published articles, but substitute “Forthcoming” for page numbers or DOI.</td>
</tr>
</tbody>
</table>
Supporting Information

Authors can submit essential supporting files and multimedia files along with their manuscripts. All supporting information will be subject to peer review. All file types can be submitted, but files must be smaller than 10 MB in size.

Authors may use almost any description as the item name for a supporting information file as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 Table,” and so forth.

Supporting information files are published exactly as provided, and are not copyedited.

Supporting information captions

List supporting information captions at the end of the manuscript file. Do not submit captions in a separate file.

The file number and name are required in a caption, and we highly recommend including a one-line title as well. You may also include a legend in your caption, but it is not required.

Example caption

S1 Text. Title is strongly recommended. Legend is optional.

In-text citations

We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If you cite supporting information in the text, citations do not need to be in numerical order.

Read the supporting information guidelines for more details about submitting supporting information and multimedia files.

Figures and Tables

Figures

Do not include figures in the main manuscript file. Each figure must be prepared and submitted as an individual file.

Cite figures in ascending numeric order upon first appearance in the manuscript file.

Read the guidelines for figures.

Figure captions
Figure captions must be inserted in the text of the manuscript, immediately following the paragraph in which the figure is first cited (read order). Do not include captions as part of the figure files themselves or submit them in a separate document.

At a minimum, include the following in your figure captions:

- A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). Match the label of your figure with the name of the file uploaded at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”).
- A concise, descriptive title

The caption may also include a legend as needed.

Read more about figure captions.

Tables

Cite tables in ascending numeric order upon first appearance in the manuscript file.

Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do not submit your tables in separate files.

Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place legends, footnotes, and other text below the table.

Read the guidelines for tables.

Data reporting

All data and related metadata underlying the findings reported in a submitted manuscript should be deposited in an appropriate public repository, unless already provided as part of the submitted article.

Read our policy on data availability.

Repositories may be either subject-specific (where these exist) and accept specific types of structured data, or generalist repositories that accept multiple data types. We recommend that authors select repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as long as DOIs or accession numbers are provided and the data are at least as open as CC BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of Approval. Large, international databases are more likely to persist than small, local ones.

See our list of recommended repositories.

To support data sharing and author compliance of the PLOS data policy, we have integrated our submission process with a select set of data repositories. The list is neither representative nor exhaustive of the suitable repositories available to authors. Current repository integration partners include Dryad and FlowRepository. Please contact data@plos.org to make recommendations for further partnerships.

Instructions for PLOS submissions with data deposited in an integration partner repository:

- Deposit data in the integrated repository of choice.
- Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for reviewers to gain access to the data.
- Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of the PLOS submission form. Then provide the URL passcode in the Attach Files section.
If you have any questions, please email us.

**Accession numbers**

All appropriate data sets, images, and information should be deposited in an appropriate public repository. See our list of recommended repositories.

Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability Statement. Accession numbers or a citation to the DOI should also be provided when the data set is mentioned within the manuscript.

In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these numbers must be provided at submission.

**Identifiers**

As much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:

- Ensembl
- Entrez Gene
- FlyBase
- InterPro
- Mouse Genome Database (MGD)
- Online Mendelian Inheritance in Man (OMIM)
- PubChem

Identifiers should be provided in parentheses after the entity on first use.

**Additional Information Requested at Submission**

**Funding statement**

This information should not be in your manuscript file; you will provide it via our submission system.

This information will be published with the final manuscript, if accepted, so please make sure that this is accurate and as detailed as possible. You should not include this information in your manuscript file, but it is important to gather it prior to submission, because your financial disclosure statement cannot be changed after initial submission.

Your statement should include relevant grant numbers and the URL of any funder's web site. Please also state whether any individuals employed or contracted by the funders (other than the named authors) played any role in: study design, data collection and analysis, decision to publish, or preparation of the manuscript. If so, please name the individual and describe their role.

**Competing interests**

This information should not be in your manuscript file; you will provide it via our submission system.

All potential competing interests must be declared in full. If the submission is related to any patents, patent applications, or products in development or for market, these details, including patent numbers and titles, must be disclosed in full.

**Manuscripts disputing published work**

PART D: Appendices
For manuscripts disputing previously published work, it is *PLOS ONE* policy to invite a signed review by the disputed author during the peer review process. This procedure is aimed at ensuring a thorough, transparent, and productive review process.

If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a full declaration of all competing interests. The Academic Editor will consider any such reviews in light of the competing interest.

Authors submitting manuscripts disputing previous work should explain the relationship between the manuscripts in their cover letter, and will be required to confirm that they accept the conditions of this review policy before the manuscript is considered further.

**Related manuscripts**

Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently under consideration or accepted elsewhere. If related work has been submitted to *PLOS ONE* or elsewhere, authors must include a copy with the submitted article. Reviewers will be asked to comment on the overlap between related submissions.

We strongly discourage the unnecessary division of related work into separate manuscripts, and we will not consider manuscripts that are divided into “parts.” Each submission to *PLOS ONE* must be written as an independent unit and should not rely on any work that has not already been accepted for publication. If related manuscripts are submitted to *PLOS ONE*, the authors may be advised to combine them into a single manuscript at the editor’s discretion.

PLOS does support authors who wish to share their work early and receive feedback before formal peer review. Deposition of manuscripts with preprint servers does not impact consideration of the manuscript at any PLOS journal.

Authors choosing bioRxiv may now concurrently submit directly to select PLOS journals through [bioRxiv’s direct transfer to journal service](https://journal.plos.org/biox).
PART E: POLICY BRIEF

A cost analysis of colorectal cancer screening in Lynch Syndrome, South Africa
Cost analysis of colorectal cancer screening in Lynch Syndrome, South Africa

Key messages

- Individuals with Lynch Syndrome (LS) have a high risk for colorectal cancer and the onset of cancer occurs at ages when persons are economically active and support families.

- South African families with LS have been implicated with the MMR genes, _MLH1_ and _MSH2_, which presents the highest risks (40% to 70%) for colorectal cancer (Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al. 2013).

- Colonoscopy reduced the incidence of colorectal cancer in individuals with LS by 62% and mortality by 65% to 70% (Palomaki et al. 2009; Vasen et al 2013; Snowsill et al. 2014).

- Colonoscopy screening combined with genetic testing significantly reduced the number of persons requiring intensive colonoscopy; and consequently was 92% less costly than performing colonoscopy screening only i.e. R4 932 718 ($332 617) compared to R390 308 ($26 319).

- This vast cost difference between the two strategies (colonoscopy only and colonoscopy + genetic testing) was not sensitive to discount rates, adherence rates or positivity rates of relatives.

Introduction

Lynch Syndrome, an autosomal dominant cancer syndrome, is associated with high risks for colorectal cancer, endometrial cancer and certain other cancers as a result of a mutation in one of the DNA mismatch repair (MMR) genes (Vasen et al. 2013). Mutation carriers have a lifetime risk for colorectal cancer of 25% to 75%, compared to a lifetime risk of 5%
in the general population (Bonadona et al. 2011; Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al. 2013). The highest risks are associated with MLH1 and MSH2 (40% to 70%), with lower risks associated with MSH6 (10% to 22%) (Bonadona et al. 2011; Giardiello et al. 2014; Snowsill et al. 2014; Vasen et al. 2013). The individuals included in this study were predominantly carriers of MLH1 and MSH2 mutations. Due to the autosomal dominant pattern, LS-associated mutations have a 50% chance of being passed on to a first degree relative (FDR) (Snowsill et al. 2014). FDRs (i.e. children, siblings or parents) of a mutation carrier are, therefore, considered as high risk for LS. Furthermore, colorectal cancers associated with Lynch Syndrome generally occur before the age of 50 years and thus, includes persons that are financially independent, economically active and support families (Snowsill et al. 2014). Thus, preventing or delaying cancer onset, by appropriate screening strategies, will have social as well as economic benefits for the country.

Colonoscopy is the only proven effective screening programme for colorectal cancer in LS; reducing colorectal cancer incidence by 62% and mortality by 65% to 70% (Palomaki et al. 2009; Vasen et al. 2013; Snowsill et al. 2014). Colonoscopy allows for (1) early detection of cancer and thus improved chances of curative treatment; and (2) pre-cancerous lesions to be removed before the polyps progress to cancer (EGAPP 2009; Giardello et al. 2014). For LS, biennial colonoscopy (for individuals under 30 years old) and annual colonoscopy (for individuals between 30 years to 60 years old) were recommended (Snowsill et al. 2014; Vasen et al. 2013).

Due to limited resources in the public sector in South Africa, colonoscopies are generally reserved for patients that already present with symptoms. (Thomson: GIT clinic GSH, personal communication 2015). Identifying individuals at high risk of colorectal cancer who will benefit from colonoscopy screening and leaving those at low risk of disease...
unexposed to potentially invasive screening procedures, will reduce the number of
unnecessary colonoscopies; as well as direct the use of scarce resources more appropriately
(Snowsill et al. 2014). Genetic testing for Lynch Syndrome is a cost-effective and reliable
strategy to identify individuals for colonoscopy screening (EGAPP 2009; Snowsill, et al.
2014). Currently, genetic testing for LS is offered via a research interface with the
University of Cape Town (Ramesar: Human Genetics UCT, personal communication
2014).

Colonoscopy screening and clinical genetics have a strong emphasis on prevention of
cancers which supports the Western Cape Department of Health’s strategic objective of
enhanced wellness through primary, secondary and tertiary prevention (Department of
Health: Western Cape. 2014). Furthermore, results from this study would inform on the
development of the genetic services policy framework (Department of Health: Circular
H212/2014) in terms of resource requirements and affordability of implementing an
effective Lynch Syndrome genetic testing programme.

Published data on the cost implications associated with providing a formal colonoscopy
and genetic testing screening service for patients with Lynch Syndrome in South Africa is
not available. Studies conducted in high income countries are not generalisable to South
Africa (Snowsill et al. 2014) as cost-effectiveness is context specific and linked to
available resources. (Drummond et al. 2005). This study, therefore, estimated and
compared the cost of two colonoscopy screening options for colorectal cancer from a
health provider’s perspective i.e. the cost of intensive colonoscopy for all LS and LS
suspected individuals was compared to the cost of intensive colonoscopy only for
individuals that tested positive for LS on genetic testing.
Objectives

- The average unit cost of colonoscopy was estimated.
- The average unit cost for genetic testing for diagnosing a proband and a relative with LS was estimated.
- The total numbers of colonoscopies required per strategy were projected.
- This information was utilised to estimate and compare the total cost for the two strategies.

Method

A comparative cost analysis of two screening approaches was conducted from the service provider perspective at a tertiary hospital. A total of 40 probands that fulfilled the Revised Bethesda Criteria and were selected for genetic testing between 01 November 2014 and 30 October 2015, and their relatives were assessed. From this cohort, all probands and their FDRs were analysed according to Strategy 1 (colonoscopy only). From the same cohort, probands that tested positive for a mutation and their FDRs were analysed according to Strategy 2 (genetic testing and colonoscopy). Total costs for the two screening strategies were compared. Sensitivity analyses were performed on adherence rates to colonoscopy, positivity rates of relatives and discount rates.

Key findings:

- Colonoscopy screening combined with genetic testing was 90% less costly than performing colonoscopy screening only i.e. R4 932 718 ($332 617) compared to R390 308 ($26 319). The cost difference between the two strategies was not influenced by discount rates, adherence rates or positivity rates of relatives.
- The unit cost of colonoscopy was R3 394.29 ($228.88); and with genetic counselling included it was R3 484.09 ($234.94).
• The weighted average unit cost for diagnosing a proband was R3 913 ($264) and for diagnosing a relative it was R1 300 ($88). The total cost for the cohort related to the genetic testing process was R170 805 ($11 518).

• It would cost R39 127 ($2 638) to exclude nine out of ten probands from the physical, psychological and financial implications of lifetime colonoscopy; while identifying one proband with confirmed LS.

• At a 50% positivity rate of relatives, it would cost R2 600 ($175) to exclude one FDR from lifetime colonoscopy while diagnose one FDR with LS. At a 30% positivity rate of relatives it would cost R3 900 ($262) to exclude two out three FDRs from lifetime colonoscopy; while identifying one FDR with LS.

Policy recommendations

• Implementation of a colonoscopy screening programme combined with genetic testing reduces the need for intensive colonoscopy on a large number of individuals; thus reducing the cost of colonoscopy screening. Also, a large number of low risk individuals would be saved from exposure to the physical and psychological hazards of colonoscopy.

• Colonoscopy services should be effective and accessible as genetic testing offers limited benefit without a well-functioning colonoscopy screening service.

• Genetic testing of relatives is less costly than diagnosing a proband and may be of greater benefit as the relative is more likely not to have cancer. Testing of relatives should, therefore, be strongly encouraged and accessibility to genetic testing services should be facilitated.

• Research with regards to the effectiveness of the screening programme should be conducted and this should involve a national register for Lynch Syndrome.
References


PART E: Policy Brief